

[FOREWORD](#)

[INTRODUCTION](#)

***Hexamethylene Diisocyanate***  
***CAS N°:822-06-0***

**SIDS Initial Assessment Report****for****12<sup>th</sup> SIAM**

(Paris, France, 27-29 June 2001)

**Chemical Name :** Hexamethylene diisocyanate

CAS No : 822-06-0

**Sponsor Country : Germany**

National SIDS Contact Point in Sponsor Country

**Lead Organization:**Name of lead organization: BMU (Bundesministerium für Umwelt, Naturschutz und  
Reaktorsicherheit)

Contact person: Prof. Dr. Ulrich Schlottmann

Address: Postfach 12 06 29  
D- 53048 Bonn- Bad Godesberg**History:** see next page**Comments:**

Date of Revision: 20. December 2001

## OECD/ICCA - The BUA\* Peer Review Process

Qualified BUA personnel (toxicologists, ecotoxicologists) perform a quality control on the full SIDS dossier submitted by industry. This quality control process follows internal BUA guidelines/instructions for the OECD/ICCA peer review process and includes:

- a full (or update) literature search to verify completeness of data provided by industry in the IUCLID/HEDSET
- Review of data and assessment of the quality of data
- Review of data evaluation
- Check of adequacy of selection process for key studies for OECD endpoints, and, where relevant, for non-OECD endpoints by checking original reports/publications
- Review of key study description according robust summaries requirements; completeness and correctness is checked against original reports/publications (if original reports are missing: reliability (4) not assignable)
- Review of validity of structure-activity relationships
- Review of full SIDS dossier (including SIAR, SIAP and proposal for conclusion and recommendation for further work)
- In case of data gaps, review of testing plan or rationale for not testing.

---

\* BUA (GDCh-Beratergremium für Altstoffe): Advisory Committee on Existing Chemicals of the Association of German Chemists (GDCh)

**SIDS INITIAL ASSESSMENT PROFILE**

<b>CAS No.</b>	822-06-0
<b>Chemical Name</b>	1,6-Hexamethylene diisocyanate
<b>Structural Formula</b>	O=C=N-(CH <sub>2</sub> ) <sub>6</sub> -N=C=O
<b>RECOMMENDATIONS</b>	
Currently a candidate for further work	
<b>SUMMARY CONCLUSIONS OF THE SIAR</b>	
<b>Human Health</b>	
<p>1,6-Hexamethylene diisocyanate (HDI) has acute effects: LD50, rat (oral): 746 – 959 mg/kg bw, LC50 rat (inhalation): (0.124 mg/l) 18.2ppm/4h, LD50, rabbit (dermal): 599 mg/kg bw. The observed symptoms are indicative of respiratory tract irritation.</p> <p>1,6-Hexamethylene diisocyanate is corrosive to the skin and the eye.</p> <p>1,6-Hexamethylene diisocyanate was found to induce dermal and respiratory sensitization in animals and humans. There is no threshold known for this effect.</p> <p>Inhalation studies with repeated exposures to 1,6-hexamethylene diisocyanate vapor show that the respiratory tract is the target with 1,6-hexamethylene diisocyanate showing primarily upper respiratory tract lesions (nasal cavity). 1,6-Hexamethylene diisocyanate did not show a neurotoxic effect in a combined reproduction/developmental/neurotoxicity study. Life-time inhalation exposure to rats revealed a progression of non-neoplastic respiratory tract lesions, primarily to the nasal cavity, and represented the sequelae of non-specific irritation. Based on the presence of only reversible tissue responses to irritation at the low concentration of 0.005 ppm, this concentration was a NOAEL. No carcinogenic potential in rats was observed after life-time inhalation.</p> <p>1,6-Hexamethylene diisocyanate showed no mutagenic activity <i>in vitro</i> in bacterial and in mammalian cell test systems.</p> <p>1,6-Hexamethylene diisocyanate showed no clastogenic activity <i>in vivo</i>.</p> <p>1,6-Hexamethylene diisocyanate has no effect on fertility and post-natal viability through post-natal day 4 in the rat after inhalation up to 0.299 ppm. The overall NOEL was 0.005 ppm.</p> <p>Inhalation of 1,6-hexamethylene diisocyanate during the pregnancy of rats produced maternal effects (nasal turbinate histopathology) at concentrations <math>\geq</math> 0.052 ppm. No developmental toxicity was observed up to 0.308 ppm.</p>	
<b>Environment</b>	
<p>HDI has a melting point of <math>-67</math> °C. The substance forms oily droplets in water and hydrolyses rapidly. The vapour pressure of HDI is 0.7 Pa/20 °C. A log <math>K_{ow}</math> is not determinable due to the instability in water.</p> <p>Hydrolysis of HDI was 90 % after a reaction period of 30 min in water at 20 °C. Hydrolysis products are hexamethylene diamine (HDA) and polyurea. Biodegradation tests on hexamethylene diamine (HAD) show the substance to be inherently biodegradable. Polyurea is more or less inert and because of its molecular size not bioavailable. The favourite compartment for HDA is water as suggested by the high water solubility. Mackay level I distribution for HDA is not applicable as this substance is protonated under environmental pH conditions. Due to the high solubility in water of HDA (800 g/l at 15.6 °C) and its log</p>	

Kow of 0.02 no bioaccumulation is expected.

In air HDI is indirectly photodegradable with  $t_{1/2} = 48.4$  h.

As the inherent property of HDI is to hydrolyse rapidly in an aquatic environment the ecotoxicological tests were conducted with the hydrolysis product(s) under defined conditions. The acute toxicity has been determined for fish (*Brachydanio rerio*) with a 96 h-LC<sub>0</sub> of  $\geq 82.8$  mg/l, for *Daphnia magna* with a 48h-EC<sub>0</sub> of  $\geq 89.1$  mg/l, and for algae (*Scenedesmus subspicatus*) a 72 h-EC<sub>50</sub> of  $>77.4$  mg/l and a 72h-NOEC of 11.7 mg/l A PNECaqua of 77.4  $\mu\text{g/l}$  is derived from the EC<sub>50</sub>-value for algae using an assessment factor of 1000. This factor is chosen because only short-term tests are available.

### Exposure

The world production capacity of name in full(HDI) amounts to about 110,000 t/a, thereof about 49,000 t/a are produced in the USA (2 producers), about 11,000 t/a in Japan (3 producers), and about 50,000 t/a in Western Europe (3 producers). HDI is not used as the monomer but is industrially processed to higher molecular weight compounds. These are used in industrial applications (mainly surface coatings) where especially lightfastness and weatherstability are required. Exposure to consumers cannot be excluded because there are a limited number of products that consumers can use which contain low concentrations of HDI. In certain occupational settings exposure may occur from the inappropriate use of products containing small concentrations of HDI.

### NATURE OF FURTHER WORK RECOMMENDED

The chemical is an irritant and a respiratory sensitizer without a known threshold. There is a need for further work (exposure assessment) in situations where there are dispersive uses (e.g. car lacquers). SIAM was informed that it is adequately controlled during manufacture (at 8 sites) and in industrial processes.

## FULL SIDS SUMMARY

CAS NO: 822-06-0		SPECIES	PROTOCOL	RESULTS
<b>PHYSICAL-CHEMICAL</b>				
2.1	Melting Point			-67 °C
2.2	Boiling Point			255 °C (at 1013 hPa)
2.3	Density		DIN 53217/2	1.05 g/cm <sup>3</sup> at 25 °C
2.4	Vapour Pressure			0.7 Pa at 20 °C
2.5	log Kow ;BCF			not determinable
2.6	A Water Solubility			not determinable
	B pH			
	pKa			
2.12	Oxidation: Red. Potential			
<b>ENVIRONMENTAL FATE AND PATHWAY</b>				
3.1.1	Photodegradation		AOPWIN 1994	in air t <sub>1/2</sub> = 48.4 h (5 * 10 <sup>5</sup> OH/cm <sup>3</sup> ; under the conditions in Western Europe)
3.1.2	Stability in Water			fast hydrolysis DT90 30-50 min
3.2	Monitoring Data			in air = mg/m <sup>3</sup> in surface water = µg/l in soil/sediment = mg/kg dw in biota = mg/kg dw
3.3	Transport and Distribution		Henry Constant	not applicable
			Mackay Level 1	not applicable
3.5	Biodegradation		Activated Sludge, domestic	42 % after 28 d
			Industrial Sewage	0 % after 28 d
<b>ECOTOXICOLOGY</b>				
4.1	Acute/Prolonged Toxicity to Fish	Brachydanio rerio	92/69/EEC C.1	LC <sub>0</sub> (96 h) >= 82.8 mg/l*
4.2	Acute Toxicity to Aquatic Invertebrates	Daphnia magna	92/69/EEC C.2	EC <sub>0</sub> (48 h) >= 89.1 mg/l*
4.3	Toxicity to Aquatic Plants e.g. Algae	Scenedesmus subspicatus	92/69/EEC C.3	EC <sub>50</sub> (72 h) > 77.4 mg/l*
4.4	Toxicity to Microorganisms e.g. Bacteria	Activated Sludge	88/302/EE C	EC <sub>50</sub> (3h) = 842 mg/l*
4.5.1	Chronic Toxicity to Fish			no data
4.5.2	Chronic Toxicity to Aquatic Invertebrates			no data
4.6.1	Toxicity to Soil Dwelling Organisms			no data

CAS NO: 822-06-0		SPECIES	PROTOCOL	RESULTS
4.6.2	Toxicity to Terrestrial Plants			no data
4.6.3	Toxicity to other Non-Mammalian Terrestrial Species (incl. Birds)			no data
<b>TOXICOLOGY</b>				
5.1.1	Acute Oral Toxicity	Rat male Rat male		LD <sub>50</sub> = 746 mg/kg LD <sub>50</sub> = 959 mg/kg
5.1.2	Acute Inhalation Toxicity	Rat	OECD 403	LC <sub>50</sub> = 124 mg/m <sup>3</sup> (18.2 ppm)
5.1.3	Acute Dermal Toxicity	Rabbit male	Exposure time: 24 h	LD <sub>50</sub> = 599 mg/kg
5.2	Corrosiveness and Irritation			
5.2.1	Skin Irritation	Rabbit	OECD 404 (occlusive)	corrosive
5.2.2	Eye Irritation	Rabbit	OECD 405	corrosive
5.3	Sensitization - skin	Guinea pig	OECD 406	Sensitizing
	- lung	Guinea pig	Induction: 3 x intradermal (day 0, 2,4) or 1 x intradermal (day 0) 5 x 3h inhalation (day 0-4) Challenge: inhalation (day 21,22, 23, 28)	Sensitizing
5.4	Repeated Dose Toxicity	Rat	Inhalation, 3 weeks, 5 h/d, 5 d/week	NOEL = 0.005 ppm (0.034 mg/m <sup>3</sup> ; ca. 0.002 mg/kg bw/d)
		Rat	Inhalation, 13 weeks, 6 h/d, 5 d/week	LOEL = 0.01 ppm (0.068 mg/m <sup>3</sup> ; ca. 0.004 mg/kg bw /d)
		Rat	Inhalation, 2 years, 6h/d, 5 d/week	NOAEL = 0.005 ppm (0.034 mg/m <sup>3</sup> ; ca. 0.002 mg/kg bw/d)
5.5	Genetic Toxicity in Vitro			
A	Bacterial Test (Gene Mutation)	Salmonella typhimurium TA 98; 100, 1535 und 1537		- (with metabolic activation) - (without metabolic activation)
B	Non-Bacterial in Vitro Test	HPRT assay (CHO cells)		- (with metabolic activation) - (without metabolic activation)
5.6	Genetic Toxicity in Vivo			
	Cytogenetic assay	Mouse bone marrow cells	single inhalation	-

CAS NO: 822-06-0		SPECIES	PROTOCOL	RESULTS
5.8	Toxicity to Reproduction	Rat	OECD 422	NOEL Maternalt. (systemic toxicity) = 0.299 ppm (2.03 mg/m <sup>3</sup> ) NOEL Maternalt. (local effect in the nasal cavity)= 0.005 ppm (0.034 mg/m <sup>3</sup> ) NOEL Offspring= 0.299 ppm (0.002 mg/l)
5.9	Developmental Toxicity/Teratogenicity	Rat	OECD 414	NOEL Maternalt. (systemic toxicity)= 0.308 ppm (2.1 mg/m <sup>3</sup> ) NOEL Maternalt. (local effect in the nasal cavity)= 0.005 ppm (0.034 mg/m <sup>3</sup> ) NOEL Teratogen.: 0.308 ppm (2.1 mg/m <sup>3</sup> )
5.11	Experience with Human Exposure	Exposed workers		Sensitization (respiratory hypersensitivity, dermal sensitization) and irritation (chronic decrease in pulmonary function) predominate

\* effect data refer to the degradation products



# SIDS Initial Assessment Report

## 1. IDENTITY

<b>CAS Number</b>	822-06-0
<b>Name</b>	1,6-Hexamethylene diisocyanate / HDI
<b>Molecular formula</b>	C <sub>8</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>

**Structure:****Physico-Chemical Properties:**

HDI is a colourless or slightly yellow liquid with a melting point of -67 °C. With a density of 1.05 g/cm<sup>3</sup> (at 25 °C) HDI is not much heavier than water. The substance forms oily droplets in water and hydrolyses rapidly (Sopac & Boltromejuk 1974; Bayer AG SDS 2000). The vapour pressure of HDI is 0.7 Pa (at 20 °C) (DFG 1988). A log K<sub>ow</sub> is not determinable due to the instability in water.

The purity of the substance is given with  $> 99.5\%$  w/w (Bayer AG SDS 2000).

## 2. GENERAL INFORMATION ON EXPOSURE

The world production capacity of HDI amounts to about 110,000 t/a. This figure can be split up as follows:

USA, 2 producers:	about 49,000 t/a
Japan, 3 producers:	about 11,000 t/a
Western Europe, 3 producers:	about 50,000 t/a

HDI can be produced by phosgenation of hexamethylene diamine and by a phosgene free process. In the phosgenation process HDI is produced continuously by reacting 1,6-hexamethylene diamine with phosgene in a solvent. The solvent and excess phosgene are recovered and returned to the production process.

In the phosgene free process HDI is produced continuously by reacting 1,6-hexamethylene diamine with urea and n-butanol. Ammonia, which is formed as a by-product of the urethanization step is removed by a thermal exhaust purification. Butanol is recovered and returned to the production process. The crude HDI product is purified by distillation. Production and processing to higher molecular compounds is carried out in closed systems.

HDI is not used as the monomer. It is industrially processed to polymers like, uretdiones, isocyanurates, and biurets. Furthermore HDI can be industrially processed with polyols to higher molecular weight adducts. These products typically contain up to 0.5 % residual monomer HDI. They are mainly used in industrial or professional applications of surface coatings with excellent lightfastness and weatherstability even without stoving.

The Swedish product register gives the information that HDI is present in 18 products available to consumers. Most products are hardeners for paints but also for sealants, caulking and putty compounds and adhesives. HDI is present only at low concentrations (all below 0.5 % and typically approx. 0.3 %).

In the Danish product register (June 2001) there is a total of 385 products containing HDI. Most products (340) have HDI concentrations between 0 and 1 %; however there are also products that contain HDI in amounts of 20 to 100 %. Product types are adhesives, binding agents, process regulators and paints, lacquers and varnishes.

HDI may be reformed when HDI-based materials are heated to decomposition leading to HDI exposure.

### 2.1 Environmental Exposure and Fate

#### 2.1.1 Environmental Exposure

At Bayer production and processing of HDI takes place in closed systems. The exhaust air is connected to a thermal exhaust purification plant (TAR). Thus during normal operation of the TAR no HDI is emitted into the atmosphere (HDI was no subject for the official German Emission

Declaration). There is no waste water from production. If cleaning of the operation plant is needed, the used solvent for cleaning is burned; devices with little dirt are treated with high pressure jet of water; this is disposed in the biological water purification plant. Due to the rapid hydrolysis of HDI and negligible amounts of HDI reaching the sewage system, no analysis of HDI is made at the sewage treatment plant outlet.

An exposure of sewage treatment plants or the terrestrial compartment to HDI is unrealistic as HDI hydrolyses rapidly.

There is no information on emission of HDI at other production / processing sites.

HDI can be released into the environment during spray applications of polymer paints containing residual amounts of monomer HDI.

### 2.1.2 Environmental Distribution and Fate

The environmental fate and distribution of HDI is determined by its property to react rapidly with water.

Sopac & Boltromejuk (1974) have reported that three main findings determine the result of the hydrolysis of HDI:

1. HDI is not soluble in the low mg/l range in water without another solvent. It forms oily droplets in water.
2. The diisocyanate groups of HDI react with water forming the diamine and CO<sub>2</sub>.
3. The diisocyanate groups of HDI can also react with the amine already formed by hydrolysis, resulting in oligo- and than polyurea.

Sopac & Boltromejuk (1974) found in a test on the stability of HDI in drinking water the reduction of the substance was 90 % after a reaction period of 30 min. Initial concentration of HDI was 200 mg/l, no organic solvent was used, and the temperature was 20°C. The reaction rate was dependent on the initial concentration of HDI and on the temperature. From this paper it can be concluded that emissions of HDI into the aquatic environment via effluent from a sewage treatment plant will not occur. The ratio of the formed hydrolysis products is strongly dependent on test procedures (slow or fast stirring, duration of stirring...).

There are several test on biodegradation of the hydrolysis product HDA available. In a MITI I test 56 % biodegradation (on the upward trend) were found after 2 weeks (CITI, 1992). In addition there is a BOD<sub>5</sub>/COD ratio of 104.8 % available (Institut Kuhlmann, 1989). As the BOD<sub>5</sub> was measured using industrial activated sludge, a statement concerning the ready biodegradability of HDA cannot be made based on this test. In a Zahn-Wellens test on HDA the pass level for inherent biodegradation was reached (Zahn/Wellens 1980). Therefore, HDA is classified at least as inherently biodegradable. Polyurea is more or less inert and because of it's molecular size not bioavailable. A test with HDI and the resulting hydrolysis products on ready biodegradation showed 42 % biodegradation after 28 days. The way of introducing the test substance was by direct weight.

A distribution calculation according to Mackay is not appropriate for the chemical HDI, due to its hydrolysing properties. If HDI reaches into water it hydrolyses to HDA and polyurea. A Mackay level I distribution for HDA is also not applicable as this substance is protonated under environmental pH conditions. However, the high water solubility suggests that HDA would largely partition into the water environment (OECD SIDS Hexamethylene diamine). Bioaccumulation of HDA is not expected due to its high water solubility of 800 g/l at 15.6 °C as well as a log  $K_{ow}$  of 0.02.

HDI reaching into the air will be photodegraded by OH-radicals, as a calculation according to Atkinson shows. The half-life due to indirect photodegradation of HDI is calculated to be 48.4 hours. The calculated half-life is regarded as worst case, since HDI will react with air humidity.

For assessment purposes it is assumed that HDI released via wastewater hydrolyses completely to HDA before reaching surface waters. This is a worst-case scenario as the other hydrolysis product polyurea is not bioavailable.

## **2.2 Human Exposure**

The main process to manufacture HDI is by a phosgenation process. Thus special safety measures are taken to prevent any risk of exposure. For HDI itself occupational exposure limit values are laid down: In Germany a maximum limit value (MAK, TRGS 900) with 0.005 ml/m<sup>3</sup> is sound. The same value is sound for short term exposure (15 minutes). In the USA the same value with 0.005 ml/m<sup>3</sup> as TLV-TWA exists: a short term exposure limit value has not been established.

Personal protection equipment needs to be worn at the workplace depending on the extent of contact with the product as well as with coating material. Special advice for different workplaces and operations are given.

Exposure to consumers cannot be excluded because there are a limited number of products that consumers can use which contain low concentrations of HDI. In certain occupational settings exposure may occur from the inappropriate use of products containing small concentrations of HDI..

### 3. HUMAN HEALTH HAZARDS

#### Effects on Human Health

#### 3.1 Acute Oral Toxicity

The LD<sub>50</sub> resulting from a single oral (gavage) administration ranged from 746 to approximately 959 mg/kg bw for the male rat (Smyth 1969; Union Carbide Co. 1964, Bayer 1970). Soon after dosing the animals appeared to be extremely sluggish. All deaths occurred within the first day.

Conclusion: The acute toxicity of HDI after oral administration is moderate.

#### 3.2 Acute Inhalation Toxicity

Several studies have evaluated the acute inhalation toxicity of HDI.

The inhalation LC<sub>50</sub> in rats of both sexes was determined to be 124 mg/m<sup>3</sup> (= 18.2 ppm) for 4 hours of exposure to HDI vapour according to the OECD Test guideline 403 (Bayer 1997). Exposures to concentrations of  $\geq 55.08$  mg/m<sup>3</sup> (= 8.1 ppm) were followed by concentration-dependent signs indicative of respiratory tract irritation, such as bradypnea, dyspnea, laboured breathing pattern, rales, nostril/snout area with red encrustations, cyanosis, prostration (lying on belly), reduced motility, ungroomed haircoat, hypothermia, decrease in body weights, and piloerection.

In rats, Woolrich (1973) as cited in NIOSH (1978) reported a 6 hour value of 0.385 mg/l, while Bunge et al. (1976) and BAYER (1970) reported 4 hour LC<sub>50</sub> values of 0.31 and 0.15 mg/l respectively, and BAYER (1970) reported a 1 hour LC<sub>50</sub> of 0.29 mg/l. For mice Lomonova & Frolova (1968) as cited in NIOSH (1978) reported 0.03 mg/l for a 2 hour exposure. Limited information was provided in all these studies on the mode of exposure, generation and characterization of test atmospheres therefore the assessment of acute inhalation toxicity is based on the most recent BAYER study (1997).

Conclusion: The evaporated HDI has a high acute inhalation toxicity to rats.

#### 3.3 Acute Dermal Toxicity

The dermal LD<sub>50</sub> following a 24-hour application of the test material to the skin is approximately 599 mg/kg bw in rabbits (Smyth 1969; Union Carbide Co. 1964). All deaths occurred within 24 hours after dosing. No information available with regard to clinical signs and local effects.

Conclusion: The acute toxicity of HDI after dermal administration is moderate.

### **3.4 Skin Irritation**

There is one study available which was conducted according to OECD guideline (Schreiber 1981). Immediately after patch removal all treated animals showed severe oedema and erythema (grade 4). 24 hours later there were induration and necrosis at the application site of all animals. No reversibility could be observed at the end of the post observation period of 8 days.

Conclusion: HDI is corrosive to the skin when tested according to the OECD Guideline 404 (Schreiber 1981).

### **3.5 Eye Irritation**

There is one study available which was conducted according to OECD guideline (Schreiber 1981). The examination of the eyes showed already 1 hour after instillation severe effects in all animals with regard to cornea, iris and conjunctivae. All effects had a tendency to get worse during the 8 day post observation period. Sometimes the examination of the eyes was impossible due to swelling.

Conclusion: HDI is corrosive to the eye when tested according to the OECD Guideline 405 (Schreiber 1981).

### **3.6 Sensitization**

#### **3.6.1 Skin Sensitization**

HDI was found to be positive in mice using ear swelling test (Gad 1986, Karol 1996, Thorne 1987) and the murine local lymph node assay (Hilton 1995). Using a guinea pig model (Buehler Test and Maximization Test according to OECD Guideline 406) several studies reported positive findings (Basketter 1996, Zissu 1998, Clemmensen 1984, Bayer 1983)

Conclusion: HDI was found to induce dermal sensitization in animals.

#### **3.6.2 Respiratory Sensitization**

Using a standard approach that included either three intradermal injections (one per day) or 5x3 hrs inhalation exposures, including one additional intradermal injections, followed by inhalation challenge with HDI, acetylcholine and conjugate by inhalation, the lung sensitization potential of HDI was examined in guinea pigs (Bayer 1996). This study provides clear evidence that HDI is a respiratory sensitizer in this guinea pig bioassay.

### 3.7 Repeated Dose Toxicity

In a 21-day inhalation study (Sangha 1984) rats were exposed up to 0.300 ppm (2.04 mg/m<sup>3</sup>) of HDI vapor. A sub-set of animals was allowed a two-week period for recovery. There were no mortality and no effects on body weight, feed consumption, clinical chemistry, hematology, urinalysis and gross pathology observed. Compound related ocular and nasal irritation were observed in animals exposed to HDI concentration  $\geq 0.0175$  ppm ( $\geq 0.119$  mg/m<sup>3</sup>). At 0.005 ppm (0.034 mg/m<sup>3</sup>) and 0.0175 ppm (0.119 mg/m<sup>3</sup>) the changes were minimal to mild in severity, and were similar to the control even though the incidence was slightly higher in the 0.0175 ppm males. There was recovery at 0.0175 (0.119 mg/m<sup>3</sup>) and 0.15 ppm (1.02 mg/m<sup>3</sup>), but not at 0.3 ppm. The NOEL was 0.005 ppm (0.034 mg/m<sup>3</sup>).

A 90-day inhalation study (Shiotsuka 1988) was conducted with HDI. Rats were exposed to vapor concentrations of 0, 0.01, 0.04, and 0.14 ppm (0, 0.068, 0.272 and 0.952 mg/m<sup>3</sup>). There were no compound related effects on mortality, body weight, clinical chemistry, hematology, urinalysis, gross pathology or organ weights. The only compound-related findings were ocular irritation and histopathologic lesions of the anterior nasal cavity. Ocular irritation occurred in all HDI-treated animals. Hyperplasia and/or squamous metaplasia of the respiratory epithelium were the most important lesions in both sexes. Hyperkeratosis, mucus cell hyperplasia and inflammatory cell infiltration were also observed in the nasal cavity. These histopathological lesions were observed at all three concentrations. The concentration of 0.01 ppm (0.068 mg/m<sup>3</sup>) was considered to approximate a threshold for respiratory tract lesions, but a clear NOEL was not established for this study.

A combined reproductive/developmental/neurotoxicity study according to OECD Guideline 422 was conducted with HDI (Astroff 1999, 2000a). Rats were exposed, via whole body exposure, to either 0, 0.005, 0.053, or 0.299 ppm (0.034, 0.361 or 2.033 mg/m<sup>3</sup>) during a 14-day pre-mating phase, up to a 14-day mating phase, and a 21-day gestation phase. Neurobehavioral testing (automated measures of activity and a functional observational battery) was conducted before exposure, after the pre-mating phase, and before termination. Evidence of toxicity was demonstrated in the 0.299 ppm and to a lesser extent in the 0.053 ppm dose group. Microscopic alterations in the nasal cavity, primarily epithelial hyperplasia, squamous metaplasia, chronic-active inflammation, and more seriously, degeneration of the olfactory epithelium were observed at concentrations  $\geq 0.053$  ppm ( $\geq 0.361$  mg/m<sup>3</sup>). No histopathological effects were observed in the 0.005 ppm dose level. No effects on neurologic parameters (functional observation battery; assessment of motor and locomotor activity) were seen at any dose level. This means the no-observed-effect-level (NOEL) for neurotoxicity was 0.299 ppm (2.033 mg/m<sup>3</sup>). The NOEL for hematology and clinical chemistry for this study was 0.299 ppm (2.033 mg/m<sup>3</sup>), too. Therefore the overall NOEL was 0.005 ppm (0.034 mg/m<sup>3</sup>).

A combined chronic toxicity/oncogenicity study (Shiotsuka 1989) with rats according to OECD Guideline 453 was conducted with HDI using concentrations of 0, 0.005, 0.025 and 0.164 ppm (0.034, 0.17 and 1.115 mg/m<sup>3</sup>) HDI vapor. The exposure regimen was 6 hours/day, 5 days/week for one year (chronic toxicity assessment) or two years (toxicity and oncogenicity assessment). There

were no compound related effects on mortality, ophthalmology, clinical biochemistry, urinalysis and organ weights. Those effects determined to be compound related were transient ocular irritation in males, small but consistent decrease in body weight of females and slight anemia in females at 0.164 ppm (1.115 mg/m<sup>3</sup>). Compound-related non-neoplastic histopathologic changes in the nasal cavity and to a lesser extent the lungs were also observed. Nasal lesions in the interim (1-year) sacrifice were restricted to the nasal mucosa at all exposure concentrations. The following nasal lesions were observed: hyperkeratosis, hyperplasia of the squamous epithelium, chronic active inflammation, squamous metaplasia, mucus secretory cell or goblet cell hyperplasia, hyaline droplet degeneration and minimal degeneration of the olfactory epithelium. All of these lesions were also observed after two years of exposure. The most prominent lesion was degenerative changes in the olfactory epithelium (destruction of epithelial architecture, atrophy, focal erosion or ulceration) The changes in the olfactory epithelium were concentration-related in terms of incidence and severity, and displayed progression with duration of exposure. Lung lesions were epithelialization, interstitial pneumonia or macrophage accumulation in alveolar space in both sexes at mid- and high dose groups after two years of exposure. No clear concentration-response relationship was observed in the lungs. No evidence of compound-related oncogenicity was found. A maximum Tolerated Dose (MTD) was achieved at high dose based on decrease in body weight and slight anemia of females and microscopic changes in the nasal cavity of both sexes. Analysis of the results from the principal study revealed that compound-related effects were limited to histopathology in the nasal passages. Although some lesions were noted in the nasal tract of animals from all exposure groups, Fourman et al. (1994) concluded that the olfactory epithelial degeneration should be considered as the significant effect in this study, with a NOAEL of 0.005 ppm (0.034 mg/m<sup>3</sup>) and a LOAEL of 0.025 ppm (0.17 mg/m<sup>3</sup>), because it followed a concentration-response relationship for both incidence and severity. The data for this lesion show its absence at the lowest concentration with parallel increases in both incidence and severity at the two highest concentrations. For the other lesions, including chronic inflammation, mucus cell hyperplasia, epithelial hyperplasia, hyaline droplet degeneration, and squamous metaplasia no concordance in incidence and severity was found. In response to an irritant, the character of lesions in the nasal tract such as squamous metaplasia, mucus cell hyperplasia, and hyaline droplet formation appears to be more adaptive than adverse..

Conclusion: The major conclusion from the available inhalation studies is that the respiratory tract is the target with HDI showing primarily upper respiratory tract lesions (nasal cavity). HDI does not pose a neurotoxic hazard. Life-time inhalation exposure to rats revealed a progression of non-neoplastic respiratory tract lesions, primarily to the nasal cavity, and represented the sequelae of non-specific irritation. Based on the presence of only reversible tissue responses to irritation at the low concentration of 0.005 ppm (0.034 mg/m<sup>3</sup>), this concentration was a NOAEL.

For respiratory sensitization see section 3.6.2.

### 3.8 Genotoxicity (Gene Mutation)

HDI was tested in two independent bacterial reverse mutation assays, using *S. typhimurium* tester strains in the presence and absence of metabolic activation (Andersen 1980, CMA data 1998a,



Wagner 2000). Both studies took the volatility of the test compound into account (vapor phase exposure). Some details (i.e. doses, positive control) of the study published in the open literature are missing but the recent study confirmed the result. HDI did not induce any mutagenic activity with any of the tester strains with and without metabolic activation. While the toxicity criteria for a valid test outlined in the protocol have not been met, the data generated, which includes acceptable positive control responses, do not indicate the presence of any mutagenic activity (CMA data 1998a, Wagner 2000).

HDI was also tested in the CHO/HPRT Mutation Assay (CMA data 1998b, Wagner 2000). HDI did not cause a positive response in the non-activated systems and S9-activated systems and was concluded to be negative. The criteria for a valid study (i.e. marked mutagenic effect in the positive control) were met

No further data are available with regard to the induction of gene mutation by HDI.

Conclusion: HDI showed no mutagenic activity in bacterial and in mammalian cell test systems.

### **3.9a Genotoxicity: (Cytogenicity) in Vitro**

No data available

Conclusion: See Cytogenetic in Vivo (chapter 3.9b)

### **3.9b Genotoxicity (Cytogenicity) in Vivo**

The clastogenic potential of HDI as measured by its ability to induce micronucleated polychromatic erythrocytes in bone marrow following inhalation exposure (CMA data 1998c, Wagner 2000). Mice were once exposed to HDI vapors up to 1.5 ppm (10.2 mg/m<sup>3</sup>) for 6 hours. No animals died during the course of the study. Mice exposed to HDI at 0.15 ppm (1.02 mg/m<sup>3</sup>) had no apparent test substance effects. Mice exposed to 0.75 and 1.5 ppm (5.1 and 10.2 mg/m<sup>3</sup>) showed considerable weight losses. Reductions of 2 to 17% in the ratio of polychromatic erythrocytes to total erythrocytes were observed in the test substance-treated males relative to the air control group at 48 hour harvest. No significant increase in micronucleated polychromatic erythrocytes in test substance-treated groups relative to the respective air control group was observed at 24, or 48 hours after exposure.

Conclusion: HDI showed no clastogenic activity in vivo.

## **3.10 Carcinogenicity**

A combined chronic toxicity/oncogenicity study (Shiotsuka 1989) with rats according to OECD Guideline 453 was conducted. Male and female Fischer 344 rats were exposed to HDI using

concentrations of 0, 0.005, 0.025 and 0.164 ppm (0, 0.034, 0.17 and 1.152 mg/m<sup>3</sup>) HDI vapor. A Maximum Tolerated Dose (MTD) was established at the highest concentration and no compound-related oncogenicity was observed (for detailed reference, see chapter 3.7).

Conclusion: After life-time inhalation of HDI no carcinogenic potential in rats was observed.

### 3.11 Toxicity to Reproduction

To evaluate the potential for HDI administered via inhalation, to elicit reproductive, developmental, and neurotoxicological effects in the rat a screening test was conducted in accordance with the OECD Guideline 422 (Astroff 1999, 2000a). Rats were exposed to either 0, 0.005, 0.053, or 0.299 ppm (0, 0.034, 0.361 and 2.03 mg/m<sup>3</sup>) during 14-day pre-mating phase, up to a 14-day mating phase, and a 21-day gestation phase. Evidence of microscopic alterations in the nasal cavity was demonstrated in the 0.299 ppm and to a lesser extent in the 0.053 ppm dose group. No effects on any reproductive or neurologic parameters or any effects on pup growth and development were observed at any dose level.

Conclusion: HDI has no effect on the reproduction (including neonatal development) in the rat after inhalation up to 0.299 ppm (2.03 mg/m<sup>3</sup>). The overall NOEL was 0.005 ppm (0.034 mg/m<sup>3</sup>).

### 3.12 Developmental Toxicity

A developmental toxicity study was conducted with HDI in the rat according to OECD Guideline 414 (Astroff 1999, 2000b). Inseminated rats were exposed to concentrations of 0, 0.005, 0.052, or 0.308 ppm (0, 0.034, 0.354 or 2.1 mg/m<sup>3</sup>) HDI via inhalation on days 0 through 19 of gestation. No clinical signs and no changes in body weight gain during gestation were observed in dams. Test compound-related maternal effects were restricted to histopathological findings in the nasal cavity of the 0.308 and 0.052 ppm dose groups. No pathological alterations were noted in the larynx, trachea, or lungs in any dose group. No test compound-related effects were observed on any reproductive parameter, or any embryonic endpoints, including pre/post-implantation loss and resorptions. There were no effects on litter size or the number of fetuses per implantation site and no effects on fetal or placental weights were observed. No test compound-related fetal external, visceral, or skeletal findings were observed. No effect on the fetal or litter incidence of total malformations or variations was observed and there was no difference in the incidence of malformations between males and females.

Conclusion: Inhalation of HDI during the pregnancy of rats produced maternal effects (nasal turbinate histopathology) at concentrations  $\geq 0.052$  ppm ( $\geq 0.354$  mg/m<sup>3</sup>). No developmental toxicity was observed up to 0.308 ppm (2.1 mg/m<sup>3</sup>).

### 3.13 Other Toxicological Endpoints

#### Sensory Irritation

Sensory irritation studies using laboratory animal models demonstrated evidence of sensory irritation but no evidence of pulmonary irritation to HDI. Sangha et al. (1981) reported a 3-hour RD50 (concentration required to reduce respiratory rate by 50%) of 1.17 mg/m<sup>3</sup> (0.17 ppm) using Swiss Webster mice. A comparable study using male Fisher 344 rats (Sangha 1982) resulted in a 30-minute RD50 of 9.94 mg/m<sup>3</sup> (1.42 ppm). The exposure of female Sprague Dawley rats resulted in a 3-hour RD50 of 11.83 mg/m<sup>3</sup> (1.69 ppm) (Mobay 1987a). In a study to assess the effects of repeated exposures on respiratory rate, female Sprague Dawley rats were exposed 3 hours/day for 5 consecutive days to a mean concentration of 8.084 mg/m<sup>3</sup> (1.17 ppm). The extent of daily decrease in respiratory rate of approximately 60%, relative to pre-exposure mean for day 1, showed that repeated exposures did not produce a cumulative effect on respiratory rate depression during daily exposures (Mobay 1987b).

#### Health Effects In Workers

Adverse health effects reported for humans are primarily related to the respiratory tract and to some extent to the exposed skin (ATSDR 1998; DFG 1996, 1998). The findings in exposed workers are consistent with the findings in laboratory animals. Sensitization (dermal sensitization, respiratory hypersensitivity) and irritation (chronic decrease in pulmonary function) predominate and cross-sensitivity of humans to diisocyanates such as TDI and MDI have been described. However, a correlation between HDI-specific IgE or IgG and occupational asthma has not been firmly established. Small cohorts, lack of mechanistic information, and limited information on exposure in the human studies preclude establishment of a concentration-response relationship for pulmonary sensitization. A few human studies were identified that described health effects evaluations associated with measured or reconstructed exposure concentrations for HDI. Brorson et al. (1990) reported no adverse health effects following a single 7.5-hour exposure at concentrations of HDI ranging from 25 to 29 µg/m<sup>3</sup> (3.6 to 4.3 ppb). In a second report a matched case-control epidemiologic study of a production plant population presented information from workers exposed for approximately three years (Shepperly & Hathaway, 1991). Exposures were generally less than 34 µg/m<sup>3</sup> (5 ppb) with occasional excursions in the range of 69 -137 µg/m<sup>3</sup> (10-20 ppb). No significant difference in pulmonary function data was detected. A follow up study of this same population reported by DeWilde & Hathaway (1994) again found no statistically significant differences in pulmonary function data. The exposure concentration was estimated to be between 0.5 and 7 ppb (3.4 and 47.6 µg/m<sup>3</sup>). The Alexandersson et al. (1987) study was determined not to be suitable for use in deriving a (L)(N)OAEL for workers, due to the fact that workers were simultaneously exposed to both the monomeric as well as the trimer forms of HDI.

**Toxicokinetics**

In animal studies the uptake of radiolabeled HDI into blood from the respiratory tract was immediate and increased linearly during exposure over a range of concentrations. In controlled studies in human volunteers, HDI (3.6 ppb for 7.5 h) appears to be rapidly absorbed via the respiratory tract and approximately up to 39% of the estimated inhaled dose is excreted in the urine which could be detected after acid hydrolysis as HDA (DFG 1996). No HDA was detectable in plasma. The relative amount excreted in feces and exhaled air or that proportion remaining bound to macromolecules and tissues have not been reported.

## 4. HAZARDS TO THE ENVIRONMENT

### 4.1 Aquatic Effects

The inherent property of HDI is to hydrolyse rapidly in an aquatic environment

Depending on the use of a solvent or not, the size of the drops when direct weight is used, and the speed of a magnetic stirrer or of ultrasonic if used, determine the quantitative proportion of the hydrolysis products HDA and polyurea. The problem with tests on HDI is the inhomogeneous distribution of the substance in the test medium water because of formation of droplets. With these droplets a "real" concentration of HDI in water is neither analytically determinable nor can a reproducible and thus reliable exposure concentration for test organisms be fixed. The pure substance HDI, as it is in the droplets, showed to be lethal to the aquatic species. The acute toxicity of HDA has to be classified as harmful and polyureas are, because of their molecular size, not bioavailable.

In the following the toxicity of the hydrolysis product(s) (see chap. 2.1.2) are reported for tests which have been conducted with specially layed down test conditions and which are thus reproducible tests.

The acute toxicity has been determined for fish with 96 h-LC<sub>0</sub> of  $\geq$  82.8 mg/l (Brachydanio rerio). The test result refers to concentration of the test substance which was calculated directly from analytically determined TOC-value. The test was conducted according to Council Directive 92/69/EEC C.1 (1992). A water accommodated fraction was prepared for testing by stirring the substance in water with Ultra turrax 60 sec/8000 rpm, 24 hours magnetic stirrer and filtration. Only one concentration was tested. The pH of the test solution was around 8 (Bayer AG 2000).

In a previous fish test, conducted according to UBA-Verfahrensvorschlag "Letale Wirkung beim Zebraabärbling" (1984), a 96 h-LC<sub>0</sub> of 22 mg/l and 96 h-LC<sub>100</sub> of 31 mg/l (Brachydanio rerio) was determined. In this test the test substance was prepared by stirring in water with Ultra turrax 60 sec/8000 rpm and waiting only for 1 hour (Bayer AG 1992). This time was regarded as too short for a complete hydrolysis of HDI because there were still oily droplets of undissolved HDI. Because of the short half-live of HDI, testing with the degradation product is required and has been conducted as seen in the first test. Therefore the second test has not been taken into account for the classification of HDI.

For acute toxicity of HDI to *Daphnia magna* a 48 h-EC<sub>0</sub> of  $\geq$  89.1 mg/l has been determined (92/69/EEC C.2 (1992)) proceeding in the same way as described in the first fish test above. The pH of the test solution was 7.8 (Bayer AG 2000).

In an algal growth inhibition test (92/69/EEC C.3 (1992)) of *Scenedesmus subspicatus* an 72 h-EC<sub>50</sub> of  $>77.4$  mg/l and a 72h-NOEC of 11.7 mg/l was observed. The proceeding for preparation of the test solution was in the same way as described in the first fish test above. However, from the stock solution a dilution series was prepared and tested. The pH of the test solution was between 7.9 and 8.2 at test start and between 9.8 and 10.2 at test end (Bayer AG 2000).

The effect of HDI on the respiration of activated sewage sludge has been tested, using a method comparable to 88/302/EEC. After 3 hours incubation an EC<sub>50</sub> of 842 mg/l was determined. In this test direct weight has been used (Bayer AG 2000).

The following endpoints on aquatic toxicologic tests are available for the pure hydrolysis product HDA (124-09-4):

#### Fish

*Lepomis macrochirus* 48 h-LC<sub>50</sub>: 73.5 mg/l and 48h-NOEC > 56 mg/l

(no information on pH; OECD SIDS on HDA)

*Pimephales promelas* 96h-LC<sub>50</sub>: 1825 mg/l

(pH: 8.0 – 8.5; E.I. du Pont, 1985b)

#### Daphnia

*Daphnia magna* 48 h-LC<sub>50</sub>: 23.4 mg/l

(pH: 7.9 - 8.5; E.I. du Pont, 1985a)

#### Algae

*Selenastrum capricornutum* 96 h-EC<sub>50</sub>: 14.8 mg/l

(pH of test solution was between 8.0 and 10.8; E.I. du Pont, 1993)

In the BUA-Report on HDI (1993) two tests are reported for HDA showing that non-neutralized and neutralized test media exhibit significant differences on the toxicity of HDA to the organisms:

#### Fish

*Leuciscus idus* 96 h-LC<sub>50</sub>: 62.2 mg/l non-neutralized

96 h-LC<sub>50</sub>: >215.0 mg/l neutralized

#### Microorganisms

*Pseudomonas putida* 20 h-EC<sub>0</sub>: 37.5 mg/l non-neutralized

20 h-EC<sub>0</sub>: 12,500 mg/l neutralized

For the derivation of the PNECaqua the effect values found in the tests with HDI and its hydrolysis products are used. Algae were the most sensitive species. An 72h-EC<sub>50</sub> of > 77.4 mg/l was found that is used as basic value for the PNECaqua. As only short-term tests are available, an assessment factor of 1000 is used.

$$\text{PNECaqua} = 77.4 \text{ mg/l} / 1000 = 77.4 \text{ } \mu\text{g/l}$$

In addition, a PNECaqua for the pure hydrolysis product HDA is derived. The lowest available effect value is the 96h-EC<sub>50</sub> of 14.8 mg/l for green algae. The pH at the concentration 25 mg/l was 9.9 at test start and 8.7 at test end. Therefore, it cannot be excluded that effects may also be caused by pH. However, at the next lowest concentration of 10 mg/l, where the alga growth was almost comparable to the control, the pH was between 9.5 and 9.7. At the next higher concentration of 25 mg/l nearly no growth could be observed at a pH between 8.1 and 10.2. Therefore, it can be assumed that the effect value of 14.8 mg/l is caused by intrinsic properties of the test substance and

not by pH and this value is used as basic value for the PNEC derivation. As only short-term tests are available an assessment factor of 1000 is used.

$$\text{PNECaqua} = 14.8 \text{ mg/l} / 1000 = 14.8 \text{ }\mu\text{g/l}$$

As it is unclear which hydrolysis products are formed to which extent under environmental conditions, it can be assumed as a worst case that all HDI released via the wastewater is hydrolysed completely to HDA before reaching surface waters. This HDA concentrations has then to be compared with the PNECaqua for HDA.

#### **4.2 Terrestrial Effects**

There are no data available.

#### **4.3 Other Environmental Effects**

There are no data available.

## 5. CONCLUSIONS AND RECOMMENDATIONS

### 5.1 Conclusions

#### Production and processing:

The world production capacity of HDI amounts to about 110,000 t/a, thereof about 49,000 t/a are produced in the USA (2 producers), about 11,000 t/a in Japan (3 producers), and about 50,000 t/a in Western Europe (3 producers). HDI is not used as the monomer but industrially processed to homopolymers and to higher molecular weight adducts. These products are mainly used in surface coatings. At Bayer production and processing of HDI takes place in closed systems. There is no emission of HDI during normal operation while producing and processing HDI.

#### Environmental behaviour:

Hydrolysis of HDI was 90 % after a reaction period of 30 min in water at 20 °C. Hydrolysis products are hexamethylene diamine (HDA) and polyurea. Biodegradation tests on HDA show the substance to be at least inherently biodegradable. Polyurea is more or less inert and because of its molecular size not bioavailable. The favourite compartment for HDA is water as suggested by the high water solubility. Mackay level I distribution for HDA is not applicable as this substance is protonated under environmental pH conditions. Due to the high solubility in water of HDA (800 g/l at 15.6 °C) and its log  $K_{ow}$  of 0.02 no bioaccumulation is expected. A calculation showed HDI to be indirectly photodegradable in air HDI with  $t_{1/2} = 48.4$  h.

As the inherent property of HDI is to hydrolyse rapidly in an aquatic environment the ecotoxicological tests were conducted with the hydrolysis product(s) under defined conditions. The acute toxicity has been determined for fish (*Brachydanio rerio*) with a 96 h-LC<sub>0</sub> of  $\geq 82.8$  mg/l, for *Daphnia magna* with a 48 h-EC<sub>0</sub> of  $\geq 89.1$  mg/l, and for algae (*Scenedesmus subspicatus*) with a 72 h-EC<sub>50</sub> of  $>77.4$  mg/l and a 72h-NOEC of 11.7 mg/l. A PNECaqua of 77.4 µg/l is derived from the EC<sub>50</sub> for algae using an assessment factor of 1000. In addition a PNECaqua of 14.8 µg/l is derived from ecotoxicity tests for the pure hydrolysis product HDA.

As it is unclear which hydrolysis products are formed to which extent under environmental conditions, it can be assumed as a worst case that all HDI released via the wastewater is hydrolysed completely to HDA before reaching surface waters. This HDA concentrations has then to be compared with the PNECaqua for HDA.

#### Human health:

HDI has acute effects: LD50, rat (oral): 746 – 959 mg/kg bw, LC50 rat (inhalation): 124 mg/m<sup>3</sup>/4h, LD50, rabbit (dermal): 599 mg/kg

HDI is corrosive to the skin and the eye.

HDI was found to induce dermal and respiratory sensitization in animals.

Inhalation studies with repeated exposures to HDI vapor show that the respiratory tract is the target showing primarily upper respiratory tract lesions (nasal cavity). did not show a neurotoxic effect in



a combined reproduction/developmental/neurotoxicity study. Life-time inhalation exposure to rats revealed a progression of non-neoplastic respiratory tract lesions, primarily to the nasal cavity, and represented the sequelae of non-specific irritation. Based on the presence of only reversible tissue responses to irritation at the low concentration of 0.005 ppm (0.034 mg/m<sup>3</sup>), this concentration was a NOAEL. No carcinogenic potential in rats was observed after life-time inhalation.

HDI showed no mutagenic activity in bacterial and in mammalian cell test systems.

HDI showed no clastogenic activity in vivo.

HDI has no effect on the reproduction (including neonatal development) in the rat after inhalation up to 0.299 ppm (2.03 mg/m<sup>3</sup>). The overall NOEL was 0.005 ppm (0.034 mg/m<sup>3</sup>).

Inhalation of HDI during the pregnancy of rats produced maternal effects (nasal turbinate histopathology) at concentrations  $\geq$  0.050 ppm ( $\geq$  0.354 mg/m<sup>3</sup>). No developmental toxicity was observed up to 0.308 ppm (2.1 mg/m<sup>3</sup>).

## 5.2 Recommendations

Concerning environment, the substance is currently of low priority for further work.

Concerning human health: The chemical is an irritant and a respiratory sensitizer without a known threshold. There is need for further work (exposure assessment) in situations where there are dispersive uses (e.g. car lacquers). SIAM was informed that exposure is adequately controlled during manufacture (at 8 sites) and in industrial processes.

## 6. REFERENCES

- Alexandersson, R. et al., *Arch. Environ. Health* 42, 367-373 (1987)
- Andersen, M. et al., *Scand. J. Work Environ. Health* 6, 221-226 (1980)
- ATSDR's Toxicological Profile, August 1998
- Astroff, A.B. et al., *Reproductive Toxicology* 14, 135-146 (2000a)
- Astroff, A.B. et al., *Teratology* 62, 205-213, (2000b)
- Astroff, A.B.: unpublished report of CMA, Study Number 98-642-PI, June 4, 1999
- Basketter, D.A. & Gerberick, G.F., *Contact Dermatitis* 35, 146-151 (1996)
- Bayer AG, Desmodur H, *Toxikologische Untersuchungen* (Bericht Nr. 2146; unpublished). Bayer AG, Institut fuer Toxikologie, Wuppertal (1970)
- Bayer AG, Hexamethylen-1,6-diisocyanat (HDI), *Untersuchungen zur sensibilisierenden Wirkung an der Meerschweinchenhaut* (Bericht Nr. 11703; unpublished). Bayer AG, Institut fuer Toxikologie, Wuppertal (1983).
- Bayer AG data, Report No. 25460, September 1996
- Bayer AG data, Report No. 25999, 19 February 1997
- Bayer AG, data 861 A/99 (2000)
- Bayer AG, data 49 A/88 (1992)
- Bayer AG, Safety Data Sheet 2000
- Brorson, T. et al., *Int. Arch. Occup. Environ. Health* 62, 385-389 (1990); Cited in: *Toxikologisch-arbeitsmedizinische Begründung von MAK-Werten*, DFG 1996, incl. Amendment (1998)
- Bunge, W. et al., *Z. Arbeitsmed., Arbeitsschutz, Prophylaxe* 4, 5-51 (1976)
- Clemmensen, S., *Drug Chem. Toxicol.* 7, 527-540 (1984)
- Chemical Manufactures Association (CMA) data; Laboratory Study Number G98AF76.502602, September 9, 1998a
- Chemical Manufactures Association (CMA) data; Laboratory Study Number G98AF76.782602, September 22, 1998b
- Chemical Manufactures Association (CMA) data; Sponsor Project Number HDI-1.0-MAB-MUTA, September 29, 1998c
- CITI, Biodegradation and bioaccumulation data of existing chemicals based on the CSCL Japan (1992)

DeWilde, A. & Hathaway, J.A., Follow-up evaluation of pulmonary function of tolonates workers at Freeport, Texas Plant (1994); Cited in : ATSDR's Toxicological Profile, August 1998

DFG, Hexamethylendiisocyanat. In: Henschler, D. (ed.), Analytische Methoden zur Pruefung gesundheitsschaedlicher Arbeitsstoffe, Bd. 1 Luftanalysen. VCH, Weinheim, 1 - 14 (1988)

E.I. du Pont de Nemours and Company, Inc., Haskell Laboratory for Toxicology and Industrial Medicine, unpublished report No. 303-85, 10.6. 1985

E.I. du Pont de Nemours and Company, Inc., Haskell Laboratory for Toxicology and Industrial Medicine, unpublished report No. 439-85, 3.10.1985

E.I. du Pont de Nemours and Company, Inc., Haskell Laboratory for Toxicology and Industrial Medicine, unpublished report No. 167-93, 30.03.1993

Foureman, G.L. et al., Inhalation Toxicology 6 (suppl.), 341-355 (1994)

Gad, S.C. et al., Toxicol. Appl. Pharmacol. 84, 93-114 (1986)

Hilton, J. et al., Toxicology Methods 5, 51-60 (1995)

Institut Kuhlmann, unpublished report 2-113-257/89, 08.05.1989

Karol, M.H. & Kramarik, J.A., Toxicology Letters 89, 139-146 (1996)

Lomonova, G.V. & Frolova, I.N. Gig. Tr. Prof. Zabol. 12, 40-44 (1968); Cited in: NIOSH, Occupational exposure to diisocyanates (Pub. No. 78-215). National Institute for Occupational Safety and Health, Cincinnati, Ohio (1978)

Mobay Corporation data, Report No. 857, June 11, 1987a

Mobay Corporation data, Report No. 930, August 26, 1987b

OECD SIDS Hexamethylene diamine

Sangha, G.K., 21-day inhalation toxicity study with HDI (Study No. 80-141-01, Report No. 469). Mobay Chemical Corp., Stilwell Kansas (1984)

Sangha, G.K., Sensory irritation study with HDI in rats (Study No. 80-141-04, Report No. 313). Mobay Chemical Corp., Stilwell Kansas (1982)

Schreiber, G., Bayer AG data, 2. April 1981

Shepperly, D. & Hathaway, J.A., Evaluation of pulmonary function of HDI exposed workers at Freeport, Texas Plant (1991); Cited in : ATSDR's Toxicological Profile, August 1998

Shiotsuka, R.N., 90-day inhalation toxicity study with 1,6-hexamethylene diisocyanate (HDI) in rats (Study No. 81-141-01, Report No. 1095). Mobay Chemical Corp., Stilwell, Kansas (1988)

Shiotsuka, R.N., Chronic inhalation toxicity study with 1,6-hexamethylene diisocyanate (HDI) in rats (Study No. 83-241-01, Report No. 1157). Mobay Chemical Corp., Stilwell, Kansas (1989)

Smyth Jr., H.F. et al., Am. Ind. Hyg. Assoc. J. 30, 470-476 (1969)

Sopac, E.D. & Boltromejuk, L.P., *Gig. Sanit.* 7, 10 -13 (1974)

Thorne P.S. et al., *Toxicol. Appl. Pharmacol* 87, 155-165 (1987)

Toxikologisch-arbeitsmedizinische Begründung von MAK-Werten, DFG 1996, incl. Amendment (1998)

Union Carbide Co., Range finding tests on 1,6-hexamethylene diisocyanate (HMDI; Report-No. 27-91; NTIA/OTS 0515600; Doc I.D. 86-870001438; Date Received 03.08.1987). Union Carbide Corporation (1964)

Wagner, V.O. et al., *Toxicological Sciences* 55, 376-382 (2000)

Woolrich, P.F., Monoisocyanates, diisocyanates and polyisocyanates – e engineering, medical control and toxicologic considerations (Technical Bulletin No. 106).The Upjohn Co, Kalamazoo, Mich., 21 pp. (1973) ; Cited in : NIOSH, Occupational exposure to diisocyanates (Pub. No. 78-215). National Institute for Occupational Safety and Health, Cincinnati, Ohio (1978)

Zahn, R. & Wellens, H., *Z. Wasser Abwasser Forsch.* 13, 1-7 (1980)

Zissu, D. et al., *Contact Dermatitis* 39, 248-251 (1998)

# ***SIDS Dossier including Robust Study Summaries***

**Existing Chemical** : ID: 822-06-0  
**CAS No.** : 822-06-0  
**EINECS Name** : hexamethylene diisocyanate  
**EC No.** : 212-485-8  
**Molecular Weight** : 168.2  
**Molecular Formula** : C<sub>8</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>

**Producer related part**

**Company** : Bayer AG  
**Creation date** : 12.08.1994

**Substance related part**

**Company** : Bayer AG  
**Creation date** : 12.08.1994

**Status** :  
**Memo** :

**Printing date** : 27.02.2002  
**Revision date** : 22.05.1995  
**Date of last update** : 13.12.2001

**Number of pages** : 1

**Chapter (profile)** : Chapter: 1, 2, 3, 4, 5, 6, 7, 8, 10  
**Reliability (profile)** : Reliability: without reliability, 1, 2, 3, 4  
**Flags (profile)** : Flags: SIDS

**1.0.1 APPLICANT AND COMPANY INFORMATION****1.0.2 LOCATION OF PRODUCTION SITE, IMPORTER OR FORMULATOR****1.0.3 IDENTITY OF RECIPIENTS****1.0.4 DETAILS ON CATEGORY/TEMPLATE****1.1.0 SUBSTANCE IDENTIFICATION****1.1.1 GENERAL SUBSTANCE INFORMATION**

**Purity type** :  
**Substance type** : organic  
**Physical status** : liquid  
**Purity** : = 98 % w/w  
**Colour** :  
**Odour** :

**Remark** : as fine chemical, Aldrich Chemical GmbH  
**Flag** : Critical study for SIDS endpoint  
 23.11.2000

**Purity type** :  
**Substance type** : organic  
**Physical status** : liquid  
**Purity** : >= 99.5 % w/w  
**Colour** :  
**Odour** :

**Remark** : Bayer AG  
**Flag** : Critical study for SIDS endpoint  
 23.11.2000

**1.1.2 SPECTRA****1.2 SYNONYMS AND TRADENAMES****1,6-Hexamethylenediisocyanat**

**Flag** : Critical study for SIDS endpoint

**1,6-Hexylendiisocyanat**

**Flag** : Critical study for SIDS endpoint

**Desmodur H (Trade name)**

Flag : Critical study for SIDS endpoint

**HDI**

Flag : Critical study for SIDS endpoint

**Hexamethylen-1,6-diisocyanat**

Flag : Critical study for SIDS endpoint

**Hexamethylendiisocyanat**

Flag : Critical study for SIDS endpoint

**Hexane, 1,6-diisocyanato- (CA-Index name)**

Flag : Critical study for SIDS endpoint

**Hexylendiisocyanat**

Flag : Critical study for SIDS endpoint

**1.3 IMPURITIES**Purity :  
CAS-No :  
EC-No :  
EINECS-Name :  
Molecular formula :  
Value : < .5 % w/wRemark : contained solvent residues and a minor volume of  
6-chloro-1-iso-cyanatohexaneFlag : Critical study for SIDS endpoint  
04.06.1998**1.4 ADDITIVES****1.5 TOTAL QUANTITY**

Quantity : 10000 - 50000 tonnes produced in 1993

Flag : Critical study for SIDS endpoint  
23.11.2000

Quantity : 10000 - 50000 tonnes produced in 1997

Flag : Critical study for SIDS endpoint  
23.11.2000

## 1. General Information

Id 822-06-0

Date 27.02.2002

**Quantity** : 10000 - 50000 tonnes produced in 2000

**Flag** : Critical study for SIDS endpoint  
23.11.2000

**1.6.1 LABELLING**

**Labelling** : as in Directive 67/548/EEC

**Specific limits** :

**Symbols** : T, , ,

**Nota** : , ,

**R-Phrases** :

(23) Toxic by inhalation

(36/37/38) Irritating to eyes, respiratory system and skin

(42/43) May cause sensitization by inhalation and skin contact

**S-Phrases** :

(26) In case of contact with eyes, rinse immediately with plenty of water and seek medical advice

(28) After contact with skin, wash immediately with plenty of plenty of water and soap

(38) In case of insufficient ventilation, wear suitable respiratory equipment

(45) In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible)

**Flag** : Critical study for SIDS endpoint  
29.03.2001

**1.6.2 CLASSIFICATION**

**Classified** : as in Directive 67/548/EEC

**Class of danger** :

toxic

**R-Phrases** :

(23) Toxic by inhalation

(36/37/38) Irritating to eyes, respiratory system and skin

(42/43) May cause sensitization by inhalation and skin contact

**Specific limits** :

**Flag** : Critical study for SIDS endpoint

**1.6.3 PACKAGING****1.7 USE PATTERN**

**Type of use** : type

**Category** : Non dispersive use

**Flag** : Critical study for SIDS endpoint  
23.06.1998

**Type of use** : industrial

**Category** : Chemical industry: used in synthesis

**Flag** : Critical study for SIDS endpoint

**Type of use** : use



## 1. General Information

Id 822-06-0

Date 27.02.2002

**Category** : Intermediates

**Flag** : Critical study for SIDS endpoint

**1.7.1 DETAILED USE PATTERN****1.7.2 METHODS OF MANUFACTURE****1.8 REGULATORY MEASURES****1.8.1 OCCUPATIONAL EXPOSURE LIMIT VALUES**

**Type of limit** : other: MAK (TRGS 900, DE)

**Limit value** : .005 ml/m<sup>3</sup>

**Short term exposure limit value**

**Limit value** : .005 ml/m<sup>3</sup>

**Time schedule** : 15 minute(s)

**Frequency** : times

**Remark** : Limit value: 0.005 ml/m<sup>3</sup> = 0.035 mg/m<sup>3</sup>

**Flag** : Critical study for SIDS endpoint

28.02.2001

(1)

**Type of limit** : other: TLV-TWA (ACGIH, US)

**Limit value** : .005 ml/m<sup>3</sup>

**Remark** : A short term exposure limit value is not established.

**Flag** : Critical study for SIDS endpoint

28.02.2001

(2)

**1.8.2 ACCEPTABLE RESIDUES LEVELS****1.8.3 WATER POLLUTION**

**Classified by** : other: Bayer AG, self classification

**Labelled by** :

**Class of danger** : 1 (weakly water polluting)

**Flag** : Critical study for SIDS endpoint

16.01.2001

**1.8.4 MAJOR ACCIDENT HAZARDS**

**Legislation** : Stoerfallverordnung (DE)

**Substance listed** : yes

**No. in Seveso directive** :

## 1. General Information

Id 822-06-0

Date 27.02.2002

**Remark** : genannt in Anhang II Nr. 4c; III Teil 2 - Kat. 2; IV Kat. 2  
(giftige Stoffe)

**Flag** : Critical study for SIDS endpoint  
23.06.1998

**1.8.5 AIR POLLUTION**

**Classified by** : TA-Luft (DE)  
**Labelled by** : other: Bayer AG  
**Number** : 3.1.7 (organic substances)  
**Class of danger** : I

**Flag** : Critical study for SIDS endpoint

**1.8.6 LISTINGS E.G. CHEMICAL INVENTORIES****1.9.1 DEGRADATION/TRANSFORMATION PRODUCTS****1.9.2 COMPONENTS****1.10 SOURCE OF EXPOSURE****1.11 ADDITIONAL REMARKS****1.12 LAST LITERATURE SEARCH**

**Type of search** : Internal and External  
**Chapters covered** :  
**Date of search** :

**Remark** : 09/1999  
**Flag** : Critical study for SIDS endpoint  
23.11.2000

**1.13 REVIEWS**

**Memo** : BUA Report No. 112 (Hexamethylenediisocyanate), VCH, April 1993

**Flag** : Critical study for SIDS endpoint  
23.11.2000

**Memo** : OECD SIDS "Hexamethylenediamine" (Canada, 1995)

**Flag** : Critical study for SIDS endpoint  
23.11.2000

## 1. General Information

**Id** 822-06-0  
**Date** 27.02.2002

**Memo** : IUCLID Dataset "Hexamethylenediamine" (ECB 2000)

**Flag** : Critical study for SIDS endpoint  
23.11.2000

### 2.1 MELTING POINT

**Value** : = -67 °C  
**Decomposition** : yes, at °C  
**Flag** : Critical study for SIDS endpoint  
27.03.2001 (3)

### 2.2 BOILING POINT

**Value** : = 255 °C at 1013 hPa  
**Flag** : Critical study for SIDS endpoint  
23.11.2000 (4)

### 2.3 DENSITY

**Type** : density  
**Value** : = 1.04 g/cm<sup>3</sup> at 20 °C  
**Flag** : Critical study for SIDS endpoint  
23.11.2000 (4)

**Type** : density  
**Value** : = 1.05 g/cm<sup>3</sup> at 25 °C  
**Method** : other: DIN 53217/2  
**Year** :  
**GLP** :  
**Test substance** :  
**Flag** : Critical study for SIDS endpoint  
29.03.2001 (3)

### 2.3.1 GRANULOMETRY

### 2.4 VAPOUR PRESSURE

**Value** : = .007 hPa at 20 °C  
**Flag** : Critical study for SIDS endpoint  
23.11.2000 (5) (6)

### 2.5 PARTITION COEFFICIENT

**Remark** : not determinable (hydrolysis)  
**Flag** : Critical study for SIDS endpoint

**2.6.1 SOLUBILITY IN DIFFERENT MEDIA**

**Solubility in Value** : Water  
 : at °C  
**pH value** :  
**concentration** : at °C  
**Temperature effects** :  
**Examine different pol.** :  
**pKa** : at 25 °C  
**Description** :  
**Stable** :

**Remark** : not determinable (hydrolysis)  
**Flag** : Critical study for SIDS endpoint

**2.6.2 SURFACE TENSION****2.7 FLASH POINT**

**Value** : = 130 °C  
**Type** :  
**Method** : other: DIN 51758  
**Year** :  
**GLP** :  
**Test substance** :

**Flag** : Critical study for SIDS endpoint  
 23.11.2000 (7) (8) (6)

**2.8 AUTO FLAMMABILITY****2.9 FLAMMABILITY**

**Result** : other: Ignition temperature: ca. 460 °C  
**Method** : other: DIN 51794  
**Year** :  
**GLP** :  
**Test substance** :

**Flag** : Critical study for SIDS endpoint  
 27.03.2001 (3)

**2.10 EXPLOSIVE PROPERTIES**

**Remark** : explosive limits: lower: 0.9 % by vol.  
 upper: 9.5 % by vol.  
**Flag** : Critical study for SIDS endpoint  
 23.11.2000 (3)

**2.11 OXIDIZING PROPERTIES****2.12 DISSOCIATION CONSTANT****2.13 VISCOSITY****2.14 ADDITIONAL REMARKS**

**3.1.1 PHOTODEGRADATION**

**Type** : other: air, indirect photolysis  
**Light source** :  
**Light spectrum** : nm  
**Relative intensity** : based on intensity of sunlight  
**Deg. product** :  
**Method** : other (calculated): according to Atkinson (AOPWIN 1994)  
**Year** :  
**GLP** :  
**Test substance** :

**Remark** : calculated half-life is based on a mean OH radical concentration of  $5 \cdot 10^5$  molecule/cm<sup>3</sup>, 12-h day under the conditions of Western Europe

**Result** : Calculation half life:  $t_{1/2} = 48.4$  h  
 $k(\text{OH})$ :  $7.95 \cdot 10^{-12}$  cm<sup>3</sup>/molecule\*s

**Reliability** : (1) valid without restriction  
 accepted calculation method

**Flag** : Critical study for SIDS endpoint  
 29.03.2001

(9)

**Type** : other: stability in air  
**Light source** :  
**Light spectrum** : nm  
**Relative intensity** : based on intensity of sunlight

**Remark** : Besides indirect photolysis, HDI in air will also be affected by air humidity. HDI is hydrolyzed to hexamethylenediamine (see also 3.8)

**Flag** : Critical study for SIDS endpoint  
 27.03.2001

**3.1.2 STABILITY IN WATER**

**Type** : abiotic  
**t<sub>1/2</sub> pH4** : at °C  
**t<sub>1/2</sub> pH7** : at °C  
**t<sub>1/2</sub> pH9** : at °C  
**Deg. product** :  
**Method** : other  
**Year** :  
**GLP** :  
**Test substance** :

**Result** : Hydrolysis of HDI at different temperatures and concentrations:

Water temperature (degree C)	HDI initial conc. (mg/l)	reaction period (min.)	reduction of HDI (%)
20	200	5	50
20	200	30	90
20	2	10	50

## 3. Environmental Fate and Pathways

Id 822-06-0

Date 27.02.2002

	20	2	50	90
	4	200	25	50
	4	200	120	90

**Reliability** : (2) valid with restrictions

**Flag** : Critical study for SIDS endpoint

27.03.2001

(10)

**3.1.3 STABILITY IN SOIL****3.2.1 MONITORING DATA**

**Remark** : Due to the rapid hydrolysis (see 3.1.2) an occurrence of HDI in the environment is not to be expected.

**Flag** : Critical study for SIDS endpoint

27.03.2001

**3.2.2 FIELD STUDIES****3.3.1 TRANSPORT BETWEEN ENVIRONMENTAL COMPARTMENTS**

**Remark** : Because of reaction with water, Henry 's constant is not determinable

**Flag** : Critical study for SIDS endpoint

23.11.2000

**3.3.2 DISTRIBUTION**

**Remark** : not determinable (hydrolysis)

**Flag** : Critical study for SIDS endpoint

27.03.2001

**3.4 MODE OF DEGRADATION IN ACTUAL USE****3.5 BIODEGRADATION**

**Type** : aerobic

**Inoculum** : activated sludge, domestic

**Concentration** : 100 mg/l related to Test substance related to

**Contact time** :

**Degradation** : 42 (±) % after 28 day(s)

**Result** :

**Deg. product** :

**Method** : other: Biodegradability - Manometric Respiratory Test Method according to Council Directive 92/69 EEC Method C.4-D

**Year** : 2000

**GLP** : yes

**Test substance** : other TS: 99.5 %



**Remark** : Inoculum: 30 mg ss/l. Test substance was added by direct weighing. Test substance hydrolyzes (see also 3.8)

**Reliability** : (2) valid with restrictions

**Flag** : Critical study for SIDS endpoint

27.03.2001

(11)

### 3.6 BOD5, COD OR BOD5/COD RATIO

### 3.7 BIOACCUMULATION

**Remark** : not determinable (hydrolysis)

**Flag** : Critical study for SIDS endpoint

27.03.2001

### 3.8 ADDITIONAL REMARKS

**Remark** : Several tests on biodegradation and ecotoxicological effects have been conducted with, as it seems, contradictory or at least inconsistent results. The following will give support for understanding and assessing test results.  
Fact is, as Sopac & Boltromejuk /1974) have reported in detail, that three main findings determine the results:

1. HDI is not soluble in the low mg/l range in water without another solvent. It forms oily droplets in water.
2. The diisocyanate ends of HDI react with water forming the amine and CO<sub>2</sub>.
3. The diisocyanate ends of HDI can also react with an amine end of an already hydrolysed (former HDI-) molecule, forming oligo- and then polyurea.

Depending on the use of a solvent or not, the size of the drops when direct weight is used, and the speed of a magnetic stirrer or of ultrasonic if used, determine the quantitative proportion of the hydrolysis products HDA and Polyurea.

The problems with tests on HDI is the inhomogeneous distribution of the substance in the test medium water because of forming droplets. With these droplets a "real" concentration of HDI in water is neither analytically determinable nor can a reproducible and thus reliable exposure concentration for test individuals be fixed.

The pure substance HDI, as it is in the droplets, showed to be lethal to the aquatic species. The acute toxicity of HDA has to be classified only as harmful and polyureas are, because of their molecular size, not bioavailable.

**Flag** : Critical study for SIDS endpoint

29.03.2001

#### 4.1 ACUTE/PROLONGED TOXICITY TO FISH

**Type** : static  
**Species** : Brachydanio rerio (Fish, fresh water)  
**Exposure period** : 96 hour(s)  
**Unit** : mg/l  
**LC0** : >= 82.8  
**Limit test** :  
**Analytical monitoring** : no  
**Method** : other: "Acute Toxicity for Fish" Council Directive 92/69/EEC C.1 (1992)  
**Year** : 2000  
**GLP** : yes  
**Test substance** : other TS: 99.5 %

**Remark** : Because of the rapid hydrolysis a water accommodated fraction (WAF) was prepared by direct weighing of 100 mg/l HDI into water. The test preparation was first stirred with an Ultra turrax for 60 sec/8000 rpm, then stirred for 24 hours with a magnetic stirrer and finally filtered. The resulting solution was analyzed to its TOC content and was the only test concentration used. The test concentration obtained by this WAF method was determined to be 82.8 mg/l.

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
27.03.2001

(11)

#### 4.2 ACUTE TOXICITY TO AQUATIC INVERTEBRATES

**Type** :  
**Species** : Daphnia magna (Crustacea)  
**Exposure period** : 48 hour(s)  
**Unit** : mg/l  
**EC0** : >= 89.1  
**Analytical monitoring** : no  
**Method** : other: "Acute Toxicity for Daphnia" Council Directive 92/69/EEC C.2 (1992)  
**Year** : 2000  
**GLP** : yes  
**Test substance** : other TS: 99.5 %

**Remark** : Because of the rapid hydrolysis a water accommodated fraction (WAF) was prepared by direct weighing of 120 mg/l HDI into water. The test preparation was first stirred with an Ultra turrax for 60 sec/8000 rpm, then stirred for 24 hours with a magnetic stirrer and finally filtered. The resulting solution was analyzed to its TOC content and was the only test concentration used. The test concentration obtained by this WAF method was determined to be 89.1 mg/l.

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
27.03.2001

(11)

#### 4.3 TOXICITY TO AQUATIC PLANTS E.G. ALGAE

**Species** : Scenedesmus subspicatus (Algae)

**Endpoint** : growth rate  
**Exposure period** : 72 hour(s)  
**Unit** : mg/l  
**EC50** : > 77.4  
**Limit test** :  
**Analytical monitoring** : no  
**Method** : other: "Algal growth inhibition test" Council Directive 92/69/EEC C.3 (1992)  
**Year** : 2000  
**GLP** : yes  
**Test substance** : other TS: 99.5 %

**Remark** : Because of the rapid hydrolysis a water accommodated fraction (WAF) was prepared by direct weighing of 125 mg/l HDI into water. The test preparation was first stirred with an Ultra turrax for 60 sec/8000 rpm, then stirred for 24 hours with a magnetic stirrer and finally filtered. The resulting solution was analyzed to its TOC content and was used as a stock solution for further dilution steps. The arithmetic mean of the analytical values showed 72 h-EC50 values for the growth rate as well as biomass to be > 77.4 mg/l. With the Dunett test the 72 h-NOEC and 72 h-LOEC for the growth rate was estimated to be 11.7 mg/l and 12.6 mg/l resp.

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
 27.03.2001

(11)

#### 4.4 TOXICITY TO MICROORGANISMS E.G. BACTERIA

**Type** : aquatic  
**Species** : activated sludge  
**Exposure period** : 3 hour(s)  
**Unit** : mg/l  
**EC50** : 842  
**Analytical monitoring** : no  
**Method** : other: Commission Directive 88/302/EEC; Official Journal of the EC L 133, Part C: Biodegradability: Test for inhibition of oxygen consumption  
**Year** : 2000  
**GLP** : yes  
**Test substance** : other TS: 99.5 %

**Remark** : Because of the rapid hydrolysis the test substance was added to water in different weights, treated 3-4 hours by ultrasound and stirred overnight before testing. The test vessel with 1000 mg/l direct weight resulted in a 3 h-EC36. The 3 h-EC50 estimated by Probit analysis gave a value of 842 mg/l.

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
 27.03.2001

(11)

#### 4.5.1 CHRONIC TOXICITY TO FISH

**4.5.2 CHRONIC TOXICITY TO AQUATIC INVERTEBRATES**

**4.6.1 TOXICITY TO SEDIMENT DWELLING ORGANISMS**

**4.6.2 TOXICITY TO TERRESTRIAL PLANTS**

**4.6.3 TOXICITY TO SOIL DWELLING ORGANISMS**

**4.6.4 TOX. TO OTHER NON MAMM. TERR. SPECIES**

**4.7 BIOLOGICAL EFFECTS MONITORING**

**4.8 BIOTRANSFORMATION AND KINETICS**

**4.9 ADDITIONAL REMARKS**

**5.0 TOXICOKINETICS, METABOLISM AND DISTRIBUTION****5.1.1 ACUTE ORAL TOXICITY**

**Type** : LD50  
**Value** : = 746 mg/kg bw  
**Species** : rat  
**Strain** :  
**Sex** : male  
**Number of animals** :  
**Vehicle** : other: undiluted  
**Doses** :  
**Method** : other: 4 dose levels; 14 day observation period  
**Year** : 1964  
**GLP** : no  
**Test substance** : other TS: no further information

**Remark** : NO. OF ANIMALS: 5/dose  
 ORIGINAL VALUE: 0.71 ml/kg (density: approx. 1.05 g/cm<sup>3</sup> at 25 oC)  
 MORTALITY: 5/5 (2 ml/kg); 5/5 (1 ml/kg); all deaths occurred within 4 hours after application; no deaths after 0.5 and 0.25 ml/kg  
 CLINICAL SIGNS: soon after dosing all animals appeared to be extremely sluggish  
 BODY WEIGHT: 9/10 gained weight during the observation period  
 GROSS EXAMINATION: congestion throughout the abdominal viscera

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint

23.10.2000

(12) (13)

**Type** : LD50  
**Value** : = 959 mg/kg bw  
**Species** : rat  
**Strain** :  
**Sex** : male  
**Number of animals** :  
**Vehicle** : other: oil  
**Doses** :  
**Method** : other: 7 dose levels; 14 days observation period  
**Year** : 1970  
**GLP** : no  
**Test substance** : other TS: chemical pure Desmodur H

**Remark** : NO. OF ANIMALS: 15/dose  
 ORIGINAL VALUE: 0.913 ml/kg (density: approx. 1.05 g/cm<sup>3</sup> at 25 oC)  
 MORTALITY: 15/15 (2 ml/kg); 14/15 (1.5 ml/kg); 11/15 (1 ml/kg); 5/15 (0.75 ml/kg); all deaths occurred within the 1 day; no deaths after 0.5; 0.25 and 0.1 ml/kg  
 CLINICAL SIGNS: soon (30 minutes - 2 hours after) after dosing all animals appeared to be extremely sluggish; duration of clinical signs: max. 7 days  
 BODY WEIGHT: no data

## 5. Toxicity

Id 822-06-0

Date 27.02.2002

**Reliability** : GROSS EXAMINATION: no data  
**Flag** : (2) valid with restrictions  
 23.10.2000 : Critical study for SIDS endpoint (14)

**5.1.2 ACUTE INHALATION TOXICITY**

**Type** : LC50  
**Value** : .124 mg/l  
**Species** : rat  
**Strain** :  
**Sex** : male/female  
**Number of animals** :  
**Vehicle** : other: no  
**Doses** :  
**Exposure time** : 4 hour(s)  
**Method** : OECD Guide-line 403 "Acute Inhalation Toxicity"  
**Year** : 1997  
**GLP** : yes  
**Test substance** : other TS: purity: 99.5 %

**Remark** : Nose-only exposure to vapour  
 NO. OF ANIMALS: 5/concentration/sex  
 Analytical monitoring of the vapour test atmosphere  
 CONCENTRATIONS: 0.055, 0.107, 0.120 or 0.151 mg/l  
 confidence interval (95%) = 0.111-0.140 mg/l  
 No gender specific susceptibility, therefore, males and females were evaluated together for the LC50-calculation

**Result** : Concentration-dependent signs indicative for respiratory tract irritation (maximum duration up to day 28); gross necropsy revealed less collapses, dark-red lungs with serous mucus in trachea, lung associated lymph nodes were enlarged  
 NO(A)EL: < 0.055 mg/l

**Reliability** : (1) valid without restriction  
**Flag** : Critical study for SIDS endpoint  
 23.10.2000 (15)

**Type** : other: sensory irritation study  
**Value** :  
**Species** : rat  
**Strain** :  
**Sex** :  
**Number of animals** :  
**Vehicle** :  
**Doses** :  
**Exposure time** : .5 hour(s)  
**Method** : other  
**Year** :  
**GLP** : no data  
**Test substance** :

**Remark** : Concentrations between 0.00077 - 0.039 mg/l caused within the first five minutes an inhibition of respiration in the sensory irritation study; afterwards tolerance was developed  
 The RD50 (50 % inhibition of respiration) was 0.00993 mg/l

**Reliability** : (2) valid with restrictions

## 5. Toxicity

Id 822-06-0

Date 27.02.2002

<b>Flag</b>	:	Critical study for SIDS endpoint	
23.10.2000			(16)
<b>Type</b>	:	other: sensory irritation study	
<b>Value</b>	:		
<b>Species</b>	:	rat	
<b>Strain</b>	:		
<b>Sex</b>	:	female	
<b>Number of animals</b>	:		
<b>Vehicle</b>	:		
<b>Doses</b>	:		
<b>Exposure time</b>	:	3 hour(s)	
<b>Method</b>	:		
<b>Year</b>	:		
<b>GLP</b>	:	yes	
<b>Test substance</b>	:	other TS: purtiy: 100 %	
<b>Result</b>	:	The RD50 for the last hour of a 3-hour exposure was 1.69 ppm (0.0118 mg/l); the no-observable-effect-level was $\geq$ 0.10 ppm (0.0007 mg/l)	
<b>Reliability</b>	:	(2) valid with restrictions	
<b>Flag</b>	:	Critical study for SIDS endpoint	
09.04.2001			(17)

## 5.1.3 ACUTE DERMAL TOXICITY

<b>Type</b>	:	LD50	
<b>Value</b>	:	= 599 mg/kg bw	
<b>Species</b>	:	rabbit	
<b>Strain</b>	:		
<b>Sex</b>	:	male	
<b>Number of animals</b>	:		
<b>Vehicle</b>	:		
<b>Doses</b>	:		
<b>Method</b>	:	other: 24-hour skin contact (occlusive); 14-day observation period	
<b>Year</b>	:	1964	
<b>GLP</b>	:	no	
<b>Test substance</b>	:	other TS: no further information	
<b>Remark</b>	:	NO. OF ANIMALS: 4/dose ORIGINAL VALUE: 0.566 ml/kg (density: approx. 1.05 g/cm <sup>3</sup> at 25 oC) MORTALITY: 3/4 (0.80 ml/kg); 1/4 (0.4 ml/kg); all deaths occurred within 24 hours after application CLINICAL SIGNS: no data LOCAL EFFECTS: no data BODY WEIGHT: 3 of the survivors lost weight or gained at a subnormal rate	
<b>Reliability</b>	:	(2) valid with restrictions	
<b>Flag</b>	:	Critical study for SIDS endpoint	
23.10.2000			(12) (13)

## 5.1.4 ACUTE TOXICITY, OTHER ROUTES

**5.2.1 SKIN IRRITATION**

**Species** : rabbit  
**Concentration** :  
**Exposure** : Occlusive  
**Exposure time** : 4 hour(s)  
**Number of animals** : 6  
**Vehicle** :  
**PDII** :  
**Result** : corrosive  
**Classification** :  
**Method** : OECD Guide-line 404 "Acute Dermal Irritation/Corrosion"  
**Year** :  
**GLP** : no  
**Test substance** : no data

**Remark** : CONCENTRATION: undiluted  
 4 hours after patch removal: 6/6 showed an erythema (grade 4) and oedemda (grade 4); 24 hours after patch removal: 6/6 showed induration and necrosis of the application site; irreversible within 8 days

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint

09.05.2001

(18)

**5.2.2 EYE IRRITATION**

**Species** : rabbit  
**Concentration** :  
**Dose** : 100 other: ul  
**Exposure time** : .5 minute(s)  
**Comment** : other: rinsing of the eyes  
**Number of animals** : 6  
**Vehicle** :  
**Result** : corrosive  
**Classification** :  
**Method** : OECD Guide-line 405 "Acute Eye Irritation/Corrosion"  
**Year** :  
**GLP** : no  
**Test substance** : no data

**Remark** : CONCENTRATION: undiluted  
 1 hour to 8 days after instillation corneal opacity, irritation of the iris, conjunctival redness and chemosis were observed in all animals; examination of the eyes was difficult due to swelling

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint

09.05.2001

(18)

**5.3 SENSITIZATION**

**Type** : Buehler Test  
**Species** : guinea pig  
**Number of animals** : 20



## 5. Toxicity

Id 822-06-0

Date 27.02.2002

**Vehicle** : no data  
**Result** : sensitizing  
**Classification** :  
**Method** : OECD Guide-line 406 "Skin Sensitization"  
**Year** : 1996  
**GLP** : no data  
**Test substance** : no data

**Remark** : induction: 10 %  
 challenge: 1 %  
 positive allergic reaction: 100 %  
**Flag** : Critical study for SIDS endpoint

09.04.2001

(19)

**Type** : Buehler Test  
**Species** : guinea pig  
**Number of animals** : 20  
**Vehicle** : petrolatum  
**Result** : sensitizing  
**Classification** :  
**Method** : OECD Guide-line 406 "Skin Sensitization"  
**Year** : 1998  
**GLP** : no data  
**Test substance** : other TS: purity 99.0 %

**Remark** : induction: 1 %  
 challenge: 0.1 %  
 positive allergic reaction: 14/20  
**Flag** : Critical study for SIDS endpoint

09.04.2001

(20)

**Type** : Guinea pig maximization test  
**Species** : guinea pig  
**Number of animals** : 20  
**Vehicle** : other: soy bean oil or a mixture of soy bean oil / 2-butanone 1:2  
**Result** : sensitizing  
**Classification** :  
**Method** : OECD Guide-line 406 "Skin Sensitization"  
**Year** : 1981  
**GLP** : no data  
**Test substance** : no data

**Remark** : induction: 1 % i.d., 10 % top  
 challenge: 0.3 %  
 positive allergic reaction: 18/20  
**Flag** : Critical study for SIDS endpoint

09.04.2001

(21)

**Type** : Guinea pig maximization test  
**Species** : guinea pig  
**Number of animals** : 17  
**Vehicle** : petrolatum  
**Result** : sensitizing  
**Classification** :  
**Method** : other  
**Year** : 1983  
**GLP** : no  
**Test substance** : other TS: purity 99 %

## 5. Toxicity

Id 822-06-0

Date 27.02.2002

<b>Remark</b>	:	induction: 10 % i.d., undiluted i.d. challenge: 1 % and 0.3 % positive allergic reaction: 16/17	
<b>Flag</b> 09.04.2001	:	Critical study for SIDS endpoint	(22)
<b>Type</b>	:	Mouse ear swelling test	
<b>Species</b>	:	mouse	
<b>Number of animals</b>	:	10	
<b>Vehicle</b>	:	other: acetone	
<b>Result</b>	:	sensitizing	
<b>Classification</b>	:		
<b>Method</b>	:	other	
<b>Year</b>	:	1986	
<b>GLP</b>	:	no data	
<b>Test substance</b>	:	no data	
<b>Remark</b>	:	induction: 5 % challenge: 0.5 % positive reaction: 67 %	
<b>Flag</b> 09.04.2001	:	Critical study for SIDS endpoint	(23)
<b>Type</b>	:	Mouse ear swelling test	
<b>Species</b>	:	mouse	
<b>Number of animals</b>	:	6	
<b>Vehicle</b>	:	other: acetone	
<b>Result</b>	:	sensitizing	
<b>Classification</b>	:		
<b>Method</b>	:	other	
<b>Year</b>	:	1996	
<b>GLP</b>	:	no data	
<b>Test substance</b>	:	no data	
<b>Remark</b>	:	induction: 0.03 - 250 ug challenge: 100 ug HDI	
<b>Flag</b> 09.04.2001	:	Critical study for SIDS endpoint	(24)
<b>Type</b>	:	Mouse ear swelling test	
<b>Species</b>	:	mouse	
<b>Number of animals</b>	:		
<b>Vehicle</b>	:	other: acetone	
<b>Result</b>	:	sensitizing	
<b>Classification</b>	:		
<b>Method</b>	:	other	
<b>Year</b>	:	1987	
<b>GLP</b>	:	no data	
<b>Test substance</b>	:	other TS: purity > 98 %	
<b>Remark</b>	:	NUMBER OF ANIMALS: 4-5	
<b>Flag</b> 09.04.2001	:	Critical study for SIDS endpoint	(25)
<b>Type</b>	:	Mouse local lymphnode assay	
<b>Species</b>	:	mouse	
<b>Number of animals</b>	:	4	

## 5. Toxicity

Id 822-06-0

Date 27.02.2002

**Vehicle** :  
**Result** : sensitizing  
**Classification** :  
**Method** :  
**Year** :  
**GLP** : no data  
**Test substance** :

**Remark** : Vehicle: acetone: olive oil (4:1)  
**Flag** : Critical study for SIDS endpoint  
 23.10.2000 (26)

**Type** : Patch-Test  
**Species** : human  
**Number of animals** :  
**Vehicle** :  
**Result** :  
**Classification** :  
**Method** : other  
**Year** :  
**GLP** : no data  
**Test substance** :

**Remark** : Positive reaction in an occupationally exposed worker who suffered from contact dermatitis and had respiratory symptoms  
**Test substance** : 1 % HDI solved in petrolatum  
**Flag** : Critical study for SIDS endpoint  
 23.10.2000 (27)

**Type** : Patch-Test  
**Species** : human  
**Number of animals** :  
**Vehicle** :  
**Result** :  
**Classification** :  
**Method** : other  
**Year** :  
**GLP** : no data  
**Test substance** :

**Remark** : 6/6 workers that suffered from occupational contact dermatitis reacted positive, while all of the 20 control patients were negative  
**Test substance** : 99 % pure HDI was diluted to 1 % in petrolatum  
**Flag** : Critical study for SIDS endpoint  
 (28) (29)

**Type** : Patch-Test  
**Species** : human

**Remark** : 0/92 emoloyers in a Swedish aircraft plant with present or previous skin disease was reported to be positive with HDI  
**Flag** : Critical study for SIDS endpoint  
 21.10.1998 (30)

**Type** : other  
**Species** : human

## 5. Toxicity

Id 822-06-0

Date 27.02.2002

**Number of animals** :  
**Vehicle** :  
**Result** :  
**Classification** :  
**Method** : other  
**Year** :  
**GLP** : no data  
**Test substance** :

**Remark** : Standard skin prick testing in healthy workers; none of the 20 tested workers reacted positive  
**Test substance** : Albumin conjugated HDI  
**Flag** : Critical study for SIDS endpoint

(31)

**Type** : other  
**Species** : human  
**Number of animals** :  
**Vehicle** :  
**Result** :  
**Classification** :  
**Method** : other  
**Year** :  
**GLP** : no data  
**Test substance** :

**Remark** : Standard skin prick test in five healthy - sporadically to isocyanates exposed - volunteers; none reacted positive  
**Test substance** : Conjugated HDI, prepolymeric HDI (Desmodur)  
**Flag** : Critical study for SIDS endpoint

(32)

**Type** : other: Lung Sensitization  
**Species** : guinea pig  
**Number of animals** :  
**Vehicle** : other: see remark  
**Result** :  
**Classification** :  
**Method** : other: see remark  
**Year** :  
**GLP** : yes  
**Test substance** : other TS: purity: 99.5 %

**Remark** : VEHICLE: Vapor exposure  
 METHOD: A standard approach was used that included either three intradermal injections (one per day) or 5x3 hrs inhalation exposures, including one additional intradermal injection, followed by inhalation challenge with the hapten, acetylcholine and conjugate by inhalation.

**Result** : The study provides clear evidence that HDI is a respiratory sensitizer in the guinea pig bioassay. These findings lend support the conclusion that succesful induction and elicitation of allergic respiratory hypersensitivity can be achieved either by intradermal and by inhalation induction exposure.

**Reliability** : (1) valid without restriction  
**Flag** : Critical study for SIDS endpoint  
 25.10.2000

(33)

**5.4 REPEATED DOSE TOXICITY**

<b>Type</b>	:	
<b>Species</b>	:	rat
<b>Sex</b>	:	female
<b>Strain</b>	:	Sprague-Dawley
<b>Route of admin.</b>	:	inhalation
<b>Exposure period</b>	:	3 hours daily
<b>Frequency of treatm.</b>	:	5 consecutive days followed by 2 non-exposure days, a sixth day of exposure
<b>Post exposure period</b>	:	4 days
<b>Doses</b>	:	1.17 ppm (0.0081 mg/l)
<b>Contrl group</b>	:	
<b>Method</b>	:	
<b>Year</b>	:	
<b>GLP</b>	:	yes
<b>Test substance</b>	:	other TS: purity: 100 %
<b>Result</b>	:	A cumulative effect on baseline respiratory rate was observed with no change in the extent of the respiratory response during exposure
<b>Reliability</b>	:	(2) valid with restrictions
<b>Flag</b>	:	Critical study for SIDS endpoint
09.05.2001		(34)
<b>Type</b>	:	
<b>Species</b>	:	rat
<b>Sex</b>	:	male/female
<b>Strain</b>	:	Sprague-Dawley
<b>Route of admin.</b>	:	other: head only vapor inhalation
<b>Exposure period</b>	:	3 weeks
<b>Frequency of treatm.</b>	:	5 h/d, 5 d/week
<b>Post exposure period</b>	:	2 weeks
<b>Doses</b>	:	0, 0.0048, 0.0175, 0.1500 and 0.300 ppm (analytically confirmed overall mean HDI concentrations)
<b>Control group</b>	:	yes, concurrent no treatment
<b>NOAEL</b>	:	= .005 ppm
<b>LOAEL</b>	:	= .0175 ppm
<b>Method</b>	:	other: see remark
<b>Year</b>	:	1984
<b>GLP</b>	:	yes
<b>Test substance</b>	:	other TS: purity 99,83 %
<b>Remark</b>	:	METHOD: other: 10 animals/sex/level; animals of each test level were split into two groups; animals of group 1 were sacrificed after the last exposure, and animals of group 2 were allowed to recover for 13 days and then sacrificed for gross necropsy and tissue collection NOMINAL CONCENTRATIONS: 0, 0.005, 0.020, 0.200 and 0.300 ppm (nominal concentrations) DEVITATION IN THE EXPOSURE REGIMEN: Originally only three exposure concentration levels were planned. Since microscopic pathological changes at the highest level were not clear, a fourth exposure level of 0.3 ppm was added. No controls wer used for 0.3 ppm. The objective of this test level was to study the microscopic pathological changes of the respiratory system at a concentration where a definite effect is seen.

**Result**

MICROSCOPIC CHANGES: The changes described above appeared to occur in a dose-related manner in the nasal cavity only. The incidence of changes in the larynx and trachea was increased in exposed groups, but severity of the changes did not increase with concentration. A consultant pathologist who reviewed the slides of the nasal cavity characterized the changes primarily as inflammatory and concluded that only 0.15 and 0.3 ppm were effect levels

: 0.300 ppm: no mortality; severe irritation of eyes and noses during exposure and at one hour post-exposure; no effect on body weights, no biologically significant effects on hematology, blood chemistry and urinalyses; decrease in the liver and kidney absolute and relative weights (females); decrease in the relative and absolute kidney weights (males); in the recovery group only relative and absolute weights in female livers, relative kidney weights in females and relative liver weights in males; no gross lesions

MICROSCOPIC CHANGES: hemorrhage, inflammatory exudate and epithelial changes in the nasal cavity (80 to 90% of the animals were affected with moderate severity); focal accumulations of mixed inflammatory cells in submucosa and a minimal to mild hyperplasia of the epithelium in the larynx and trachea; no recovery in males

0.1500 ppm: no mortality; severe irritation of eyes and noses during exposure and at one hour post-exposure; no effect on body weights; no biologically significant effects on hematology, blood chemistry and urinalyses; no effects on organ weights; no gross lesions

MICROSCOPIC CHANGES: hemorrhage, inflammatory exudate and epithelial changes in the nasal cavity (50 to 70% of the animals were affected with moderate severity) ; focal accumulations of mixed inflammatory cells in submucosa and a minimal to mild hyperplasia of the epithelium in the larynx and trachea; recovery is suggested

0.0175 ppm: no mortality; irritation of eyes and noses during exposure and at one hour post-exposure; no effect on body weights; no biologically significant effects on hematology, blood chemistry and urinalyses; no effects on organ weights; no gross lesions

MICROSCOPIC CHANGES: the changes in the nasal cavity were minimal to mild in severity, and were similar to the control even though the incidence was slightly higher; recovery is suggested.

0.005 ppm: no mortality; irritation of eyes and noses during exposure and at one hour post-exposure; no effect on body weights; no biologically significant effects on hematology, blood chemistry and urinalyses; no effects on organ weights; no gross lesions

MICROSCOPIC CHANGES: the changes in the nasal cavity were minimal to mild in severity, and were similar to the control.

**Reliability**

: (2) valid with restrictions

**Flag**

: Critical study for SIDS endpoint

09.04.2001

(35)

**Type**

:

**Species**

: rat

**Sex**

: male/female

**Strain**

: Fischer 344

**Route of admin.** : other: vapor inhalation  
**Exposure period** : approx. 13 weeks  
**Frequency of treatm.** : 6 h/day, 5 d/week  
**Post exposure period** : no  
**Doses** : 0, 0.01, 0.04 and 0.14 ppm (analytically confirmed overall mean HDI concentrations)  
**Control group** : yes, concurrent no treatment  
**LOAEL** : = .01 ppm  
**Method** : OECD Guide-line 413 "Subchronic Inhalation Toxicity: 90-day Study"  
**Year** : 1988  
**GLP** : yes  
**Test substance** : other TS: purity 99,83 %

**Remark** : NOMINAL CONCENTRATIONS: 0, 0.01, 0.04, and 0.16 ppm  
 DEVIATION IN THE EXPOSURE REGIMEN: The variation in the number of exposure days (66 to 69) was a result of different rats being sacrificed over a period of four days. During this last week all rats not removed for necropsy were still exposed.  
 CLINICAL SIGNS: rhinorrhea and ocular opacity were not considered to be compound related  
 HISTOPATHOLOGIC LESIONS: hyperplasia and/or squamous metaplasia of the respiratory epithelium; keratin was often present covering the metaplastic epithelium in the mid- and high-dose rats; mucous cell hyperplasia predominantly of respiratory epithelium and inflammatory cell infiltrate principally within subepithelial tissues

**Result** : 0.14 ppm: no mortality; ocular irritation (includes lacrimation); no effects on body weights, on clinical chemistry, hematology, urinalyses; gross pathology and organ to body weight ratios; histopathological lesions in the cranial nasal cavity anterior to the nasal papilla of both sexes (for details see the remark field)  
 0.04 ppm: no mortality; ocular irritation (includes lacrimation); no effects on body weights, on clinical chemistry, hematology, urinalyses; gross pathology and organ to body weight ratios. histopathological lesions in the cranial nasal cavity anterior to the nasal papilla of both sexes (for details see the remark field)  
 0.01 ppm: no mortality; ocular irritation (includes lacrimation); no effects on body weights, on clinical chemistry, hematology, urinalyses; gross pathology and organ to body weight ratios; histopathological lesions in the cranial nasal cavity anterior to the nasal papilla of both sexes (for details see the remark field); the lesions were minor and were seen in only a few animals

**Reliability** : (1) valid without restriction  
**Flag** : Critical study for SIDS endpoint  
 25.10.2000

(36)

**Type** :  
**Species** : rat  
**Sex** : male/female  
**Strain** : Fischer 344  
**Route of admin.** : other: whole body vapor inhalation  
**Exposure period** : 2 years  
**Frequency of treatm.** : 6 h/day, 5 d/week  
**Post exposure period** :  
**Doses** : 0, 0.005, 0.025 and 0.175 ppm (nominal concentrations)

<b>Control group</b>	: yes, concurrent no treatment
<b>NOAEL</b>	: = .005 ppm
<b>Method</b>	: other: OECD Guide-line 453
<b>Year</b>	: 1989
<b>GLP</b>	: yes
<b>Test substance</b>	: other TS: purity 99,83 %
<b>Remark</b>	<p>: Analytically confirmed overall mean HDI  CONCENTRATIONS: 0, 0.005, 0.025, and 0.164 ppm  EXPOSURE REGIMEN: Seperate groups of 10 rats/sex/level were exposed under the same exposure regime for one year (satellite group)  EXPERIMENTAL DESIGN: the exposure was conducted under dynamic conditions, the air control animals were sham-exposed (conditioned room air) under comparable conditions  HISTOPATHOLOGY: emphasis was placed on the standardization of trimming proced ures of the nasal cavity; removal of mandible, tongue and associated structures, coronal nasal sections were made from the following areas:  Level I vestibule  Level II posterior to incisor teeth  Level III prepapilla  Level IV incisive papilla  Level V first palatal ridge  Level VI second palatal ridge  Level VII first molar teeth (second molar tetth in satellite animals)  HISTOPATHOLOGIC LESIONS:  Nasal cavity:  Level I: There was increased incidence of epithelial hyperplasia or thickening with hyperkeratosis and erosion at 0.175 ppm. Septal epithelial thickness did not statistically differ between control and exposed males. In females, hyperkeratosis of the epithelium was increased in all exposed groups while epithelial hyperplasia was more frequent in 0.005 ppm and 0.025 ppm exposed groups. There was a statistically significant difference in septal epithelial thickness between control and 0.005 ppm and 0.025 ppm (but not 0.175 ppm) exposed females in the nasal vestibule.  Level II: There was prominent, minmal to mild, hyperkeratosis and erosion in both sexes exposed to 0.175 ppm of HDI. In 0.175 ppm males, the erosion was often more severe leading to ulceration. Females receiving 0.025 ppm also demonstrated increased hyperkeratosis. Squamous metaplasia genrally affecting the turbinate tips, septum, and lateral walls was extensive in 0.175 ppm rats while a combination of epithelial hyperplasia/metaplasia or mucus secretory cell hyperplasia was most prevalent in 0.005 ppm and 0.025 ppm rats o f both sexes. Inflammatin was observed in 0.025 ppm and 0.175 ppm male and female rats an was slightly more severe in the 0.175 ppm exposure groups. Thickness of the epithelium (regardless of morphologic type) covering the nasal septum, dorsal and ventral turbinates and lateral walls was statistically different from controls at all exposure levels in females and at the 0.025 ppm and 0.175 ppm levels in males.  Level III: There was decreased squamous metaplasia</p>



(compared hyperplasia/metaplasia in 0.175 ppm rats. Epithelial hyperplasia without metaplastic change was notably increased in 0.025 ppm and 0.175 ppm males and 0.025 ppm females. Hyperkeratosis was present in some 0.175 ppm rats of both sexes. Mucus secretory cell hyperplasia was increased at all exposure levels in both sexes. At this third section, hyaline droplet degeneration of epithelium along the dorsal septum and dorsal meatus was prominent in 0.005 ppm and 0.025 ppm females as well as 0.025 ppm males. Non-specific inflammation was observed in groups exposed to 0.025 ppm and 0.175 ppm. Epithelial erosion or ulceration was present in a few animals particularly at 0.1175 ppm.

Level IV: Hyaline droplet degeneration was seen in both sexes with increased incidence in all exposed groups as compared to controls, but this change was more prevalent and was graded more extensively in groups exposed to 0.025 ppm. There was notable olfactory epithelium degeneration in 0.175 ppm males and females with narrowing or atrophy and occasional focal erosion or ulceration. Epithelial hyperplasia of 0.025 ppm females and mucus secretory cell hyperplasia of all exposure groups in males and females were present. Inflammation was observed in 0.025 ppm and 0.175 ppm males and females.

Level V/VI: In controls, there was considerable minimal to mild background levels of epithelial cell mucus and hyaline droplet, degeneration particularly along the nasal turbinate scrolls, adjacent to the septum and pharyngeal duct. There was increased amounts of mucus and hyaline material after exposure to all concentration of HDI as compared with controls. Epithelial hyperplasia, usually along the septum, was seen in 0.025 ppm females while dorsal septal erosion, often associated with metaplastic change to a squamous epithelium, was seen in 0.175 ppm males. Degeneration of the olfactory epithelium was prominent in the 0.175 ppm exposure group of both sexes. Inflammation was observed in 0.025 ppm and 0.175 ppm males and females.

Level VII: Epithelial changes were similar to those of the previous two sections and only prominent changes were noted in addition to those observations. Thus the observations were less frequent and principal lesions consisted of degeneration of the dorsal olfactory epithelium of the ethmoid turbinates in 0.175 ppm males and hyaline droplet degeneration in 0.005 ppm females.

#### Lungs:

There were generally minimal to mild, focal to multifocal lesions coded as epithelialization (alveolar lining cell proliferatin), interstitial pneumonia (septal thickening, alveolar cellular content and increased alveolar lining cell prominence), or alveolar macrophage accumulation (histiocyte cells in alveolar space). When considered individually or combined there was an exposure-related incidence of these lesions in rats of both sexes exposed to 0.025 ppm or 0.175 ppm of HDI.

SATELLITE OBSERVATIONS: no statistically significant terminal body weight differences between control and exposed rats of either sex in the satellite group. Nonneoplastic or neoplastic lesions were similar but less developed than those in terminal sacrifice animals; there was no early dose-related onset of neoplastic gross tissue changes;

<b>Result</b>	<p>lesions were restricted to histopathologic alteration of nasal mucosa; after one year 0.005 ppm is considered to be a NOEL since the changes observed occurred only in one sex, were qualitatively similar to those seen in controls and did not show any concentration-dependent increase in degree.</p> <p>: 0.005 ppm: no effect on mortality rate; ocular irritation (includes lacrimation); no effects on body weights, on clinical chemistry, hematology, urinalyses; gross pathology and no significant effects on organ weights; histopathological lesions in the nasal cavity; no associated exposure-related lesions were observed in the trachea, larynx or nasal lacrimal duct (for details see the remark field)</p> <p>0.025 ppm: no effect on mortality rate; ocular irritation (includes lacrimation); no effects on body weights, on clinical chemistry, hematology, urinalyses; gross pathology and no significant effects on organ weights; histopathological lesions in the nasal cavity and lungs; no associated exposure-related lesions were observed in the trachea, larynx or nasal lacrimal duct (for details see the remark field)</p> <p>0.175 ppm: no effect on mortality rate; transient ocular irritation in males; no lesions of the eye detected by ophthalmoscopic examination; slight body weight decrease in females during the second year of exposure; hematologic effects in females (associated with slight anemia); no effects on clinical chemistry, urinalyses; gross pathology and no significant effects on organ weights; histopathological lesions in the nasal cavity and lungs; no associated exposure-related lesions were observed in the trachea, larynx or nasal lacrimal duct (for details see the remark field)</p>
<b>Reliability Flag</b>	<p>: (1) valid without restriction</p> <p>: Critical study for SIDS endpoint</p>
13.12.2001	(37) (38)
<b>Type</b>	:
<b>Species</b>	: rat
<b>Sex</b>	: male/female
<b>Strain</b>	: Sprague-Dawley
<b>Route of admin.</b>	: other: whole body vapor inhalation
<b>Exposure period</b>	: male: 28 days; female: 50 days
<b>Frequency of treatm.</b>	: 6 hours/day; 7 days/week
<b>Post exposure period</b>	: 4 days (female)
<b>Doses</b>	: 0, 0.005, 0.050 or 0.300 ppm (nominal concentrations)
<b>Control group</b>	: yes, concurrent no treatment
<b>NOAEL</b>	: .005 ppm
<b>LOAEL</b>	: .05 ppm
<b>Method</b>	: other: OECD Guide-line 422
<b>Year</b>	: 1999
<b>GLP</b>	: yes
<b>Test substance</b>	: other TS: purity: 99,7% -99.6%
<b>Remark</b>	<p>: Analytically confirmed overall (for the entire study) mean HDI</p> <p>CONCENTRATIONS: 0.005, 0.053 and 0.299 ppm</p> <p>EXPOSURE PERIOD: during a 4-day lactation phase the exposure to HDI was also discontinued for the dams.</p> <p>Deviation in the exposure regimen of the females: some of</p>

the females were exposed through gestation day 19, others were exposed through gestation day 18 only, and others were exposed through gestation day 18 and again on gestation day 20. In order to assess the impact of the deviation on the study the tissues from the respiratory tract of all females were examined microscopically. The results of these examinations did not indicate any differences between the females differentially exposed

**Result** : 0.300 ppm: microscopic effects in the nasal cavity of both sexes (epithelial hyperplasia, squamous metaplasia, chronic-active inflammation, degeneration of the olfactory epithelium); no effects on hematology, clinical chemistry, organ weights and neurologic parameters  
0.050 ppm: similar microscopic effects, albeit to a lesser extent than in the 0.300 ppm exposure group; no effects on hematology, clinical chemistry, organ weights and neurologic parameters  
0.005 ppm: No histopathological findings; no effects on hematology, clinical chemistry, organ weights and neurologic parameters  
For clinical signs and body weight in parental animals (NOAEL Parental) and pups (NOAEL F1 Offspring) see chapter 5.8 ("Toxicity to Reproduction")

**Reliability Flag** : (1) valid without restriction  
: Critical study for SIDS endpoint

25.10.2000 (39) (40)

#### 5.5 GENETIC TOXICITY 'IN VITRO'

**Type** : Ames test  
**System of testing** : S. typhimurium TA 100, TA 1537 and TA 98  
**Test concentration** : no data  
**Cycotoxic concentr.** :  
**Metabolic activation** : with and without  
**Result** : negative  
**Method** : other: without modifications as described by Ames, B.N. et al., Mutat. Res. 31, 347-364 (1975)  
**Year** : 1980  
**GLP** : no data  
**Test substance** : other TS: purity: synthetic grade from Merck-Schuchardt dissolved in DMSO

**Remark** : METABOLIC ACTIVATION: liver microsome fraction S-9 mix from rats receiving 0.1% sodium phenobarbital in the drinking water one week before they were killed  
METHOD: plates containing the same dose and compound were placed in polyethylene bags which were sealed

**Reliability Flag** : (2) valid with restrictions  
: Critical study for SIDS endpoint

26.10.2000 (41)

**Type** : Bacterial reverse mutation assay  
**System of testing** : S. typhimurium TA 98, TA 100, TA 1535 and TA 1537  
**Test concentration** : 6, 12, 20, 25, 50 and 150 uL per desiccator  
**Cycotoxic concentr.** :  
**Metabolic activation** : with and without  
**Result** : negative

**Method** : other: see remark field  
**Year** : 1998  
**GLP** : yes  
**Test substance** : other TS: purity: 99.5. %

**Remark** : METABOLIC ACTIVATION: Aroclor 1254-induced male rat liver S9 was used.  
 METHOD: The test system was exposed to the test substance via the desiccator methodology, a modification of the plate incorporation methodology originally described by Ames et al., Mutat. Res. 31, 347-364 (1975) and updated by Maron and Ames, Mutat. Res. 113, 173-215 (1983). The desiccator methodology has been shown to be an effective method for detecting the genotoxic activity of volatile and gaseous test substances (Wagner et al., Environ. Mol. Mutagen. 19, 68 (1992)).  
 Deviation from the original study protocol: The independent repeat assay was not performed because technical difficulties in dosing the test article using the desiccator methodology make further testing unwarranted.  
 The test article exposure was reduced to approx. 8 hours. After this exposure period, the plates were removed from the desiccator and incubated with the lids replaced such that the total incubation time was approx. 48 to 72 hours  
 RESULT: No precipitate was observed but toxicity generally observed at  $\geq 6\mu\text{L}$  per desiccator, with non-uniform toxicity over at least 25% of the surface of each affected plate. The non-uniform toxicity did not appear to be a function of the location or orientation of the plates in the desiccators. The non-uniform toxicity profile appears to be unique to HDI. In addition, no mutagenic activity was observed in locations on the plates where the background lawns were nontoxic (normal).

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
 02.11.2000

(42) (43)

**Type** : HGPRT assay  
**System of testing** : CHO cells  
**Test concentration** : see remark field  
**Cytotoxic concentr.** :  
**Metabolic activation** : with and without  
**Result** : negative  
**Method** : other: see remark field  
**Year** : 1998  
**GLP** : yes  
**Test substance** : other TS: purity: 99.5 %

**Remark** : METABOLIC ACTIVATION: Aroclor 1254-induced male rat liver S9 was used  
 METHOD: The assay was performed according to a protocol developed from published methodologies (Hsie et al., Mutat. Res. 86, 193-214 (1981); O'Neill et al., Mutat. Res. 45, 91-101 (1977); Wagner et al., Environ. Mol. Mutagen. 19, 68 (1992)). The desiccator methodology has been shown to be an effective method for detecting the genotoxic activity of volatile and gaseous test substances (Wagner et al. (1992)).  
 CONCENTRATIONS: initial assay: 1.0 up to 5 mL (-S9) and 1.0 up to 10 mL (+S9); independent repeat assay: 1.0 up to 10 mL

(+/-S9)

DEVIATION FROM THE PROTOCOL: negative controls exhibited mutant frequencies > 25% per 10 to the sixth clonable cells in the initial and the repeat assay; therefore this deviation was not considered to have any adverse impact on the conclusion or integrity of the study. Exposure time was increased from 5 hours to 7.5 hours.

CONCURRENT CYTOTOXICITY: initial assay: no toxicity, i.e., cloning efficiency <=50%, at any dose level (relative cloning efficiency was 121% and 78% at the highest dose tested without and with metabolic activation, respectively); independent repeat assay: no toxicity, i.e., cloning efficiency <=50%, at any dose level (relative cloning efficiency was 74% and 114% at the highest dose tested without and with metabolic activation, respectively)

**Reliability** : (1) valid without restriction  
**Flag** : Critical study for SIDS endpoint  
 02.11.2000

(44) (43)

**5.6 GENETIC TOXICITY 'IN VIVO'**

**Type** : Micronucleus assay  
**Species** : mouse  
**Sex** : male/female  
**Strain** : CD-1  
**Route of admin.** : other: whole body vapor inhalation  
**Exposure period** : once for 6 hours  
**Doses** : 0.15, 0.75 and 1.5 ppm (nominal concentrations)  
**Result** :  
**Method** : other: the protocol complies with OECD Guide-line 474  
**Year** : 1998  
**GLP** : yes  
**Test substance** : other TS: purity: 99.5 %

**Remark** : ANALYTICAL CONCENTRATIONS: 0.14, 0.80 and 1.47 ppm  
**Result** : TOLERATION BY THE ANIMALS: no animals died; increased activity was the only sign observed during the exposures in all treated groups; all animals in the 2 highest exposure groups that were on study until Day 3 had lost weight compared to their pretest weight; no macroscopic changes were observed at necropsy in any dose group  
 RATIO OF POLYCHROMATIC ERYTHROCYTES TO TOTAL ERYTHROCYTES:  
 reduction of 2 to 17% in test substance treated males at 48 hours (at 0.15 ppm 17%; at 0.75 ppm 8% and at 1.5 ppm 2%)  
 MICRONUCLEATED POLYCHROMATIC ERYTHROCYTES: no significant increase was observed in male and female mice at 24, or 48 hours

**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
 02.11.2000

(45) (43)

**5.7 CARCINOGENICITY**

**Species** : rat  
**Sex** : male/female

## 5. Toxicity

Id 822-06-0

Date 27.02.2002

**Strain** : Fischer 344  
**Route of admin.** : inhalation  
**Exposure period** : 2 years  
**Frequency of treatm.** : 6 h/day, 5 d/week  
**Post exposure period** : no  
**Doses** : 0.035; 0.175 or 1.2 mg/m<sup>3</sup> (0.005; 0.025 or 0.175 ppm)  
**Result** :  
**Control group** : yes, concurrent vehicle  
**Method** : other: Test guidelines: EPA/TSCA, subpart D, 798.3320 (1988); OECD No. 453 (1981); MAFF/Japan, 59 NohSan No. 4200 (1985)  
**Year** :  
**GLP** : yes  
**Test substance** :  
  
**Remark** : see also chapter 5.4  
**Result** : no increase of tumor incidences at any concentration  
**Flag** : Critical study for SIDS endpoint

(38)

## 5.8.1 TOXICITY TO FERTILITY

**Type** : other: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  
**Species** : rat  
**Sex** : male/female  
**Strain** : Sprague-Dawley  
**Route of admin.** : other: whole body vapor inhalation  
**Exposure period** : male: 28 days; female: 50 days  
**Frequency of treatm.** : 6 hours/day, 7 days/week  
**Premating exposure period**  
     **Male** : 14 days  
     **Female** : 14 days  
**Duration of test** : 54 days  
**No. of generation studies** :  
**Doses** : 0, 0.005, 0.050 or 0.300 ppm (nominal concentrations)  
**Control group** : yes, concurrent no treatment  
**Method** : other: OECD Guide-line 422  
**Year** : 1999  
**GLP** : yes  
**Test substance** : other TS: purity:99.7% -99.6%  
  
**Remark** : Analytically confirmed overall (for the entire study) mean HDI  
 CONCENTRATIONS: 0.005, 0.053 and 0.299 ppm  
 EXPOSURE PERIOD: during a 4-day lactation phase the exposure to HDI was also discontinued for the dams.  
 Deviation in the exposure regimen of the females: some of the females were exposed through gestation day 19, others were exposed through gestation day 18 only, and others were exposed through gestation day 18 and again on gestation day 20. In order to assess the impact of the deviation on the study the tissues from the respiratory tract of all females were examined microscopically. The results of these examinations did not indicate any differences between the females differentially exposed.  
 NOAEL PARENTAL:

<b>Result</b>	<p>The NOEL for clinical signs during pre-mating and mating phases, for both and females, was 0.300 ppm. The NOEL for effects on body weight during pre-mating and mating phases was 0.050 ppm for the females and 0.300 ppm for the males. The NOEL for maternal clinical signs and for effects on maternal body weight during gestation phase was 0.300 ppm. The NOEL for maternal clinical signs and for effects on maternal body weight and food consumption during the lactation phase was 0.300 ppm. NOAEL F1 OFFSPRING: The NOEL for pup clinical signs and for effects on pup body weight during lactation phase were 0.300 ppm.</p> <p>: There were no statistically significant effects on the mating, fertility, or gestation indices. There were no effects observed on the days to insemination, gestation length, or total number of implantation sites. The NOEL for effects on reproductive parameters was 0.300 ppm. There were no statistically significant effects on litter size, total number of pups born, sex distribution, mean weight of viable pups, mean number of viable pups or number of stillborn pups. No statistically significant effects were observed on the live birth, viability, lactation, or birth indices. The NOEL for effects on litter parameters was 0.300 ppm. The pathology findings, including hematology, clinical chemistry, organ weights, gross and microscopic evaluations, and the neurotoxicological evaluations are presented in chapter 5.4 ("Repeated Dose Toxicity").</p>
<b>Reliability Flag</b>	<p>: (1) valid without restriction : Critical study for SIDS endpoint</p>
25.10.2000	(39) (40)

#### 5.8.2 DEVELOPMENTAL TOXICITY/TERATOGENICITY

<b>Species</b>	: rat
<b>Sex</b>	: female
<b>Strain</b>	: Sprague-Dawley
<b>Route of admin.</b>	: other: whole body vapor inhalation
<b>Exposure period</b>	: days 0 through 19 of gestation
<b>Frequency of treatm.</b>	: daily 6 hours
<b>Duration of test</b>	: 20 days
<b>Doses</b>	: 0, 0.005, 0.050 or 0.300 ppm (nominal concentrations)
<b>Control group</b>	: yes, concurrent no treatment
<b>NOAEL maternal tox.</b>	: .005 ppm
<b>NOAEL teratogen.</b>	: .3 ppm
<b>Method</b>	: OECD Guide-line 414 "Teratogenicity"
<b>Year</b>	: 1999
<b>GLP</b>	: yes
<b>Test substance</b>	: other TS: purity:99.7% -99.6%
<b>Remark</b>	: Analytically confirmed overall (for the entire study) mean HDI CONCENTRATIONS: 0.005, 0.052 and 0.308 ppm
<b>Result</b>	: 0.300 ppm: no mortality; no clinical signs; no test compound related effects on maternal body weight, uterine weight, and net body weight; microscopic changes within the nasal

cavity;  
 No effects on reproductive parameters; no embryotoxicity; no litter effects; no fetal external, visceral, and skeletal malformations  
 0.050 ppm: no mortality; no clinical signs; no test compound related effects on maternal body weight, uterine weight, and net body weight; microscopic changes within the nasal cavity (to a lesser extent compared to the 0.300 ppm exposure group)  
 No effects on reproductive parameters; no embryotoxicity; no litter effects; no fetal external, visceral, and skeletal malformations  
 0.005 ppm: no mortality; no clinical signs; no test compound related effects on maternal body weight, uterine weight, and net body weight; no microscopic changes within the nasal cavity  
 No effects on reproductive parameters; no embryotoxicity; no litter effects; no fetal external, visceral, and skeletal malformations

**Reliability** : (1) valid without restriction  
**Flag** : Critical study for SIDS endpoint  
 13.12.2001

(46)

### 5.8.3 TOXICITY TO REPRODUCTION, OTHER STUDIES

### 5.9 SPECIFIC INVESTIGATIONS

### 5.10 EXPOSURE EXPERIENCE

**Remark** : Three male volunteers were shortly exposed to HDI (insufficiently reported study). 0.007 mg/m<sup>3</sup> (0.001 ppm) was not smelled; 0.035 mg/m<sup>3</sup> (0.005 ppm) was smelled by 1/3 man and 0.07 mg/m<sup>3</sup> (0.01 ppm) by all; at 0.14 mg/m<sup>3</sup> (0.02 ppm) HDI was clearly perceptible and led to a slight irritation in two volunteers; 0.7 mg/m<sup>3</sup> (0.1 ppm) had an acrid odor and led to clear irritation of eyes and throat.

**Flag** : Critical study for SIDS endpoint

(14)

**Remark** : Case reports as well as systematic examinations of occupationally exposed workers described as main symptoms asthmatic reactions, bronchial hyperreactivity, alveolitis, changes in several parameters of lung function and the occurrence of IgG or IgE antibodies against HDI bound to human serum albumin. In most of the cases the exposure occurred to spray applications of polyurethane coatings that based on HDI prepolymers and had an average residual monomer content of ≤ 0.5 %; additionally during production and processing the workers were exposed (for details see cited references).

**Flag** : Critical study for SIDS endpoint  
 02.11.2000  
 (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63)  
 (64) (65) (66) (31) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78)



- Remark** : Several cases of cross reactivity between different isocyanates (HDI, TDI, MDI etc.) were reported in exposed workers.
- Flag** : Critical study for SIDS endpoint  
(79) (80) (81) (82) (68) (83) (71) (72) (77)
- Remark** : Biomonitoring:  
In an inhalation trial five healthy male non-smokers (age 36 to 50 years; four out of five were exposed in former times) were exposed to an average HDI concentration of 0.025 mg/m<sup>3</sup> for 7.5 h; the absorbed dose/person was estimated to be about 0.1 mg; in the hydrolysed urine 0.0018 to 0.014 mg of the related 1,6-hexamethylene diamine (HDA) was determined within 28 h corresponding to 11 to 21 % of the absorbed HDI concentration; HDA elimination was rapid and the half life was in the range of 1.1 to 1.4 h; HDA was not detectable in the plasma (detection limit: 0.0005 mg/l).
- Flag** : Critical study for SIDS endpoint  
(32)
- Remark** : Biomonitoring:  
One volunteer was exposed to an average HDI concentration of 0.03 mg/m<sup>3</sup> for 7.5 h and the absorbed HDI amount was estimated to be around 0.1 mg; in the hydrolysed urine 0.01 mg HDA was detected within 28 h corresponding to around 10 % of the absorbed HDA; HDA half life was about 1.4 h and more than 90 % were excreted via the urine within the first four h.
- Flag** : Critical study for SIDS endpoint  
(84)
- Remark** : Biomonitoring:  
Exposure of five volunteers to HDI (0.15 to 0.33 mg/m<sup>3</sup>) lasting 15 min. led to detectable amounts of HDA in the hydrolysed urine; the highest HDA concentration was noted after 30 min. (around 0.0185 mg/mmol creatinine) while after 6 to 8 h less than 0.0003 mg HDA/mmol creatinine was detectable (with one exception).
- Flag** : Critical study for SIDS endpoint  
(85)
- Remark** : 41 male car painters (age: 20 to 64; 58 % smokers) with an average of 7 year employment that were exposed to HDI concentrations of about 0.001 mg/m<sup>3</sup> (paint with 0.5 to 1 % unreacted HDI and 40 to 50 % HDI biuret trimer in the hardener) with brief peaks had an increased incidence in eye, nose and throat irritation and chronic bronchitis but no differences in spirometry was noted in comparison to controls (car painters and mechanics without HDI exposure). Closing volume in relation to vital capacity was increased suggesting a "small airways disease" on Monday before work and tended to increase during work week.

**Flag** : Critical study for SIDS endpoint (86)

**Remark** : 81 workers (age: 21 to > 50 years; 57 % smokers) engaged in the production of HDI showed normal lung functions (cross-sectional analysis) though the 20 ppb TLV was occasionally exceeded.

**Flag** : Critical study for SIDS endpoint (87)

**Remark** : 36 male car painters (average age of 39.8 years, 55 % smokers, mean employment of 16.5 years) participated in a follow-up study with measurement of lung function and exposure measurement. The mean HDI exposure was 0.0015 mg/m<sup>3</sup> and the mean HDI biuret trimer (HDI<sub>BT</sub>) exposure 0.09 mg/m<sup>3</sup>. The smoking car painters had greater yearly reduction in forced vital capacity, forced expiratory volume and closing volume compared to smoking controls, while the nonsmoking car painters showed no differences in lung volumes in comparison to nonsmoking controls. The impairment correlated with the frequency of high peak exposure to HDI-BT but not with the mean exposure to diisocyanates.

**Flag** : Critical study for SIDS endpoint (88)

**Remark** : In a prospective evaluation of 150 workers exposed to HDI and its trimer during 18 months specific IgG- and IgE-antibodies against HDI bound to human serum albumin were found in 13 and 5 % of the exposed group resp.. However, there was insufficient evidence about the relationship between antibody titer and clinical disease.

**Flag** : Critical study for SIDS endpoint (89)

**Remark** : An examination of 11 workers with occupational asthma after HDI exposure indicated that people with a heterozygous alpha1 antitrypsin phenotype tend to bronchial hyperreactivity in contrast to people with homozygous alpha1 antitrypsin phenotype.

**Flag** : Critical study for SIDS endpoint (90)

**Remark** : The results of a 2.5-year follow-up of workers in a polyurethane molding process with combined exposure to isocyanate and organic solvents indicate that long-term exposure to isocyanates may contribute to impaired pulmonary function.

**Flag** : Critical study for SIDS endpoint (91)  
21.10.1998

**Remark** : Peripheral blood mononuclear cells of workers (n=19) with confirmed diisocyanate-induced occupational asthma can be

stimulated in vitro with DHI-HSA antigens to produce basophil-activating histamine releasing factors and monocyte chemoattractant protein 1.

**Flag** : Critical study for SIDS endpoint (92)  
21.10.1998

**Remark** : Biomonitoring: There was a linear association of HDI air concentration (0.30 to 97.7 ug/m<sup>3</sup>) with urinary HDA (1.36 to 27.7 ug/g creatinine) liberated by acid hydrolysis from its conjugates in post shift samples of 19 men.

**Flag** : Critical study for SIDS endpoint (93)  
22.10.1998

**Remark** : The apoptosis seems to increase in white blood cells of isocyanate-workers after inhalation of HDI (5 ppb for 15 minutes followed by 10 ppb for 105 minutes; number of HDI-exposed workers unknown).

**Flag** : Critical study for SIDS endpoint (94)  
21.10.1998

**Remark** : Biomonitoring: Three volunteers were each exposed to 11.9, 20.5 and 22.1 ug HDI/m<sup>3</sup> for 2 hours. After hydrolysis under alkaline conditions the average urinary excretion of HDA was 39 %. The average urinary elimination half-time for HDA was 2.5 h. No HDA could be found in hydrolysed plasma.

**Flag** : Critical study for SIDS endpoint (95)  
21.10.1998

**Remark** : Biomonitoring:  
Urine samples were taken from sprayers wearing personal protective equipment and spraying in booths or with local exhaust ventilation, from bystanders, and from unexposed subjects. HDA was detected in four sprayers and one bystander out of 22 workers. No HDA was detected in the urine of unexposed subjects.

**Flag** : Critical study for SIDS endpoint (96)  
02.11.2000

**Remark** : This pilot study documents HDI contamination on a number of surfaces in auto body shops. In addition, it has been shown evidence of substantial epicutaneous exposure to HDI in auto body shop workers and the inadequacy of latex gloves in exposures.

**Flag** : Critical study for SIDS endpoint (97)  
02.11.2000

#### 5.11 ADDITIONAL REMARKS

**Type** : other

**Remark** : revision: 10/00

**Flag** : Critical study for SIDS endpoint  
25.10.2000

**Type** : other

**Remark** : An overall perspective of the toxicology of hexamethylene  
diisocyanate is given in some comprehensive publications

**Flag** : Critical study for SIDS endpoint  
26.10.2000

(98) (99)

**Type** : other

**Remark** : An overall perspective of the sensitization potential

**Flag** : Critical study for SIDS endpoint  
02.11.2000

(100)

- (1) Technische Regeln für Gefahrstoffe -TRGS 900- Grenzwerte in der Luft am Arbeitsplatz 'Luftgrenzwerte', Ausgabe Oktober 2000 (BARBl. 10/2000 S. 34-63), Richtlinie 2000/39/EG v. 08-06-2000 (ABl. L 142 vom 16-06-2000 S. 47)
- (2) ACGIH, Treshold limit values and biologic exposure indices for 2000. American Conference of Governmental Industrial Hygienists, Cincinnati, Ohio, (2000)
- (3) Bayer AG, DIN-Sicherheitsdatenblatt. Bayer AG, Leverkusen (2000)
- (4) Aldrich, Katalog Handbuch Feinchemikalien. Aldrich-Chemie GmbH & Co. KG, Steinheim, 706 (2000)
- (5) DFG, Hexamethylendiisocyanat. In: Henschler, D. (ed.), Analytische Methoden zur Pruefung gesundheitsschaedlicher Arbeitsstoffe, Bd. 1. Luftanalysen. VCH, Weinheim, 1-14 (1988)
- (6) Sorbe, Sicherheitstechnische Kenndaten, Gefahrenindex chemischer Stoffe, 9. Ergaenzungsl.. ecomed, Landsberg, 39 (1988)
- (7) Eisenmann, K.-H. & Zenner, K.-F., Isocyanate. In: Ullmanns Encyklopaedie der technischen Chemie, Band 13, 4. Aufl.. Verlag Chemie, Weinheim, 347-358 (1977)
- (8) Hommel, G., Handbuch der gefaehrlichen Gueter. Merkblatt 365, 4. Aufl.. Springer-Verlag, Berlin, 365 (1985)
- (9) Calculation Bayer AG (2000), Photodegradation with SCR-AOP / AOPWIN 1994
- (10) Sopac, E.D. & Boltromejuk, L.P., Gig. Sanit. 7, 10-13 (1974)
- (11) Bayer AG data 861 A/99 (2000)
- (12) Smyth Jr., H.F. et al., Am. Ind. Hyg. Assoc. J. 30, 470-476 (1969)
- (13) Union Carbide Co., Range finding tests on 1,6-hexamethylene diisocyanate (HMDI; Report No. 27-91; NTIS/OTS 0515600; Doc I.D. 86-870001438; Date Received 03.08.1987). Union Carbide Corporation (1964)
- (14) Bayer AG, Desmodur H, Toxikologische Untersuchungen (Bericht Nr. 2146; unpublished). Bayer AG, Institut fuer Toxikologie, Wuppertal (1970)
- (15) Bayer AG data, Report No. 25999, 19 February 1997
- (16) Sangha, G.K., Sensory irritation study with HDI in rats (Study No. 81-341-04, Report No. 313). Mobay Chemical Corp., Stilwell, Kansas (1982)
- (17) Mobay Corporation data, Report No. 857, June 11, 1987

- (18) Schreiber, G., Bayer AG data, 2. April 1981
- (19) Basketter, D.A. & Gerberick, G.F., Contact Dermatitis 35, 146-151 (1996)
- (20) Zissu, D. et al., Contact Dermatitis 39, 248-251 (1998)
- (21) Clemmensen, S., Drug Chem. Toxicol. 7, 527-540 (1984)
- (22) Bayer AG, Hexamethylen-1,6-diisocyanat (HDI), Untersuchungen zur sensibilisierenden Wirkung an der Meerschweinchenhaut (Bericht N r. 11703; unpublished). Bayer AG, Institut fuer Toxikologie, Wuppertal (1983)
- (23) Gad, S.C. et al., Toxicol. Appl. Pharmacol. 84, 93-114 (1986)
- (24) Karol, M.H. & Kramarik, J.A., Toxicology Letters 89, 139-146 (1996)
- (25) Thorne, P.S. et al., Toxicol. Appl. Pharmacol. 87, 155-165 (1987)
- (26) Hilton, J. et al., Toxicology Methods 5, 51-60 (1995)
- (27) Kanerva, L. et al., Allergic contact dermatitis from isocyanates. Current topics in contact dermatitis. Springer-Verlag, Berlin, 368-373 (1989)
- (28) Cartwright, P.H. et al., Contact Dermatitis 23, 252 (1990)
- (29) Wilkinson, S.M. et al., Contact Derm. 25, 94-96 (1991)
- (30) Brunze, M. et al., Contact Dermatitis 34, 336-340 (1996)
- (31) Hjortsberg, U. et al., Br. J. Ind. Med. 44, 824-828 (1987)
- (32) Brorson, T. et al., Int. Arch. Occup. Environ. Health 62, 385-389 (1990)
- (33) Bayer AG data, Report No. 25460, September 1996
- (34) Mobay Corporation data, Report No. 930, August 26, 1987
- (35) Sangha, G.K., 21-day inhalation toxicity study with HDI (Study No. 80-141-01, Report No. 469). Mobay Chemical Corp., Stilwell, Kansas (1984)
- (36) Shiotsuka, R.N., 90-day inhalation toxicity study with 1,6-hexamethylene diisocyanate (HDI) in rats (Study No. 81-141-01, Report No. 1095). Mobay Chemical Corp., Stilwell, Kansas (1988)
- (37) Foureman, G.L. et al., Inhalation Toxicology 6 (Suppl.), 341-355 (1994)

- (38) Shiotsuka, R.N., Chronic inhalation toxicity and oncogenicity study with 1,6 hexamethylene diisocyanate (HDI) in rats (Study No. 83-241-01, Report No. 1157). Mobay Chemical Corp., Stilwell, Kansas (1989)
- (39) Astroff, A.B. et al., Reproductive Toxicology 14, 135-146 (2000)
- (40) Astroff, A.B.: unpublished report of CMA, Study Number 98-642-PI, June 4, 1999
- (41) Andersen, M. et al., Scand. J. Work Environ. Health 6, 221-226 (1980)
- (42) Chemical Manufactures Association (CMA) data; Laboratory Study Number G98AF76.502602, September 9, 1998
- (43) Wagner, V.O. et al., Toxicological Sciences 55, 376-382 (2000)
- (44) Chemical Manufactures Association (CMA) data; Laboratory Study Number G98AF76.782602, September 22, 1998
- (45) Chemical Manufactures Association (CMA) data; Sponsor Project Number HDI-1.0-MAB-MUTA, September 29, 1998
- (46) Astroff, A.B.: unpublished report of CMA, Study Number 98-642-RX, June 16, 1999
- (47) Ameille, J. et al., Arch. Mal. Prof. 44, 477-481 (1983)
- (48) Banks, D.E. et al., Chest 95, 414-423 (1989)
- (49) Baur, X., Allergologie 9, 487-496 (1986)
- (50) Baur, X., et al., Am. J. Ind. Med. 33, 114-122 (1998)
- (51) Belin, L. et al., J. Work Environ. Health 7, 310-311 (1981)
- (52) Broughton, A. et al., Am. J. Ind. Med. 13, 463-472 (1988)
- (53) Cartier, A. et al., J. Allergy Clin. Immunol. 83, 214 (1989)
- (54) Cartier, A. et al., J. Allergy Clin. Immunol. 84, 507-514 (1989)
- (55) Charles, J. et al., Thorax 31, 127-136 (1976)
- (56) Cockcroft, D.W. & Mink, J.T., Can. Med. Assoc. 121, 602-604 (1979)
- (57) Cockcroft, D.W. et al., J. Allergy Clin. Immunol. 63, 151 (1979)
- (58) Cockcroft, D.W., Ann. Allergy 48, 93-95 (1982)
- (59) Cvitanovic, S. et al., Int. Arch. Occup. Environ. Health 61, 483-486 (1989)

- (60) Deschamps, F. et al., *J. Toxicol. Environ. Health, Part A*, 54, 335-342 (1998)
- (61) Ferguson, K. et al., *J. Occup. Health Safety* 12, 31-40 (1996)
- (62) Filatova, V.S. et al., *Gig. Tr. Prof. Zabol.* 12, 3-7 (1968)
- (63) Franklin, P.J. et al., *Am. J. Ind. Med.* 37, 431-437 (2000)
- (64) Gerritsen, W.B., *Chem. Weekbl.* 51, 269-270 (1955)
- (65) Grammer, L.C. et al., *J. Allergy Clin. Immunol.* 83, 215 (1989)
- (66) Hathaway, J.A. et al., *J. Occup. Environ. Med.* 41, 378-383 (1999)
- (67) Innocenti, A. et al., *Med. Lavoro* 77, 191-194 (1986)
- (68) Keskinen, H. et al., *Clin. Allergy* 18, 597-604 (1988)
- (69) Malo, J.L. et al., *J. Allergy Clin. Immunol.* 72, 413-419 (1983)
- (70) Nielsen, J. et al., *Scand. J. Work Environ. Health* 11, 51-54 (1985)
- (71) O'Brien, I.M. et al., *Clin. Allergy* 9, 1-6 (1979)
- (72) Patterson, R. et al., *Am. Rev. Respir. Dis.* 141, 226-230 (1990)
- (73) Redlich, C.A. et al., *Scand. J. Work Environ. Health* 23, 227-231 (1997)
- (74) Selden, A.I. et al., *Scand. J. Work Environ. Health* 15, 234-237 (1989)
- (75) Tyrer, F.H., *J. Soc. Occup. Med.* 29, 22-24 (1979)
- (76) Vandenplas, O. et al., *Am. Rev. Respir. Dis.* 145, A503 (1992)
- (77) Wass, U. & Belin, L., *J. Allergy Clin. Immunol.* 83, 126-135 (1989)
- (78) Welinder, H. et al., *Clin. Allergy* 18, 85-93 (1988)
- (79) Baur, X. & Fruhmann, G., *Chest* 80, 73-76 (1981)
- (80) Baur, X., *J. Allergy Clin. Immunol.* 71, 197-205 (1983)
- (81) Belin, L. & Wass, U., *Eur. J. Respir. Dis. Suppl.* 62, 148-149 (1981)
- (82) Gallagher, J.S. et al., *J. Occup. Med.* 23, 610-616 (1981)



- (83) Nuorteva, P. et al., *Environ. Res.* 43, 308-316 (1987)
- (84) Dalene, M. et al., *J. Chromatogr.* 516, 405-413 (1990)
- (85) Rosenberg, C. & Savolainen, H., *Analyst* 111, 1069-1071 (1986)
- (86) Alexandersson, R. et al., *Arch. Environ. Health* 42, 367-373 (1987)
- (87) Diller, W.F. et al., *Zbl. Arbeitsmed.* 35, 85-87 (1985)
- (88) Tornling, G. et al., *Am. J. Ind. Med.* 17, 299-310 (1990)
- (89) Grammer, L.C. et al., *J. Allergy Clin. Immunol.* 82, 627-633 (1988)
- (90) Savolainen, H., *Res. Commun. Chem. Pathol. Pharmacol.* 71, 385-386 (1991)
- (91) Akbar-Khanzadeh, F. & Rivas, R.D., *J. Occup. Environ. Med.* 38, 1205-1212 (1997)
- (92) Lummus, Z.L. et al., *Toxicology* 111, 191-206 (1996)
- (93) Maitre, A. et al., *Int. Arch. Occup. Environ. Health* 69, 65-68 (1996)
- (94) Marczynski, B. et al., *Atemwegs- und Lungenkrankheiten* 20, 456-457 (1994)
- (95) Tinnerberg, H. et al., *Int. Arch. Occup. Environ. Health* 67, 367-374 (1995)
- (96) Williams, N.R. et al., *Occup. Environ. Med.* 56, 598-601 (1999)
- (97) Liu, Y. et al., *Am. J. Ind. Med.* 37, 265-274 (2000)
- (98) ATSDR's Toxicological Profile, August 1998
- (99) Toxikologisch-arbeitsmedizinische Begründung von MAK -Werten, DFG 1996; incl. amendment (1998)
- (100) ECETOC, Technical Report No. 77, 13-15, August 1999